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ABSTRACT
Chronic heart failure (CHF) is a life-altering long-term condition that contributes 
a substantial burden to our healthcare system. It is caused by a maladaptive remodeling of 
the heart mediated through fibroblast synthesis, degradation, and modification of 
extracellular matrix (ECM). It is currently managed through pharmacologic intervention 
or medical device treatment, but can be reversed only through heart transplantation. Cell 
therapy is a new approach to treating CHF that promises to prevent and potentially 
reverse cardiac remodeling through interaction with cardiac fibroblasts. Adherent bone 
marrow derived stem cells (MSC) are one of the most promising candidates for use in 
cell therapies. The major challenge hindering standard clinical application of MSC 
therapy is limited understanding of how MSC interact with heart cells to reverse 
remodeling. Numerous techniques are available to harvest, isolate, and modify MSC, 
however these techniques are believed to influence the efficacy of the treatment. Current 
techniques for evaluating efficacy of MSC treatments are either prohibitively difficult or 
significantly limited in their ability to assess functional changes. Establishing an in vitro 
platform for evaluating the influence of MSC coculture on performance characteristics of 
cardiac fibroblasts is a logical and efficient step prior to successful clinical 
implementation of MSC therapy. The objective of this research was to develop a three­
dimensional (3D) tissue model that allows investigation of the underlying mechanism
responsible for MSC mediated cardiac regeneration. The three phases of this work 
included: (1) development of a biomaterial substrate capable of sustaining fibroblast 
attachment, proliferation, and alignment, (2) development of a culture platform and 
seeding techniques capable of providing sufficient mass transport to sustain a relatively 
thick 3D scaffold populated with both fibroblasts and MSC (3) application of the 
substrate and culture platform to evaluate changes in mechanical properties and cell 
distribution resulting from MSC coculture with cardiac fibroblasts.
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Chronic heart failure is a significant problem facing the United States. In 2006, 
there were 5.8 million Americans living with heart failure [1]. The associated personal 
and economic burdens are enormous. The most common acute cause of heart failure is 
myocardial infarction (MI) [1]. Infarct-induced ischemia and hypoxia lead to myocyte 
depletion in the infarct zone and border regions, and local activation of inflammatory and 
fibroblast cell types. These two physiologic responses to MI often result in a self- 
sustaining series of detrimental structural changes to the heart. Typically termed 
maladaptive remodeling, this phenomenon is a biomechanical process that is attributed to 
changes in passive stiffness of the ventricular wall. More specifically, maladaptive 
remodeling is a consequence of changes in ventricular wall stiffness during two distinct 
phases of healing after MI. During the early post-MI phase, the stiffness of the infarct 
area is dramatically decreased. Rupture, dyskinesis, and infarct expansion arise from 
insufficient stiffness of the ventricular wall and lead to infarct expansion, dilated 
cardiomyopathy, decreased ejection fraction, and systolic heart failure. On the other 
hand, during the later post-MI healing phase, activated myofibroblasts (myoFb) increase
matrix production and organization to stiffen the infarcted region. In many cases, 
increased matrix accumulation in regions remote to the infarct accompanies local matrix 
deposition. Increased passive stiffness in remote regions prevent adequate filling of the 
ventricle during diastole, and leads to diastolic heart failure. Both cases, systolic and 
diastolic heart failure, are results of pathologic changes in passive stiffness. Prevention of 
maladaptive remodeling and regeneration of myocardial function after MI relies on a 
delicate balance of passive stiffness and therefore is profoundly influenced through the 
matrix regulation activity of cardiac fibroblasts (CFb).
Cardiac cell therapy appears to be a promising new treatment to prevent heart 
failure after MI [2]. The aim of this therapy is to enhance in situ regeneration of cardiac 
function. Modulation of the CFb response during post-MI healing is one potentially 
powerful approach that may lead to functional myocardial regeneration. Despite 
significant findings initially, cell therapy has been delayed in its transition to a standard 
treatment following MI. Delivery of bone marrow cells including mesenchymal stem 
cells (MSC) has been shown in animal models to increase positive clinical endpoints such 
as ejection fraction and survival [3, 4]. However, in multisubject human clinical trials, 
cell therapy has not significantly prevented or reversed cardiac remodeling [5]. To realize 
the potential of cardiac cell therapy, we need to elucidate the mechanism behind the 
apparent MSC-induced cardiac regeneration observed in animal models.
One pathway to increased understanding of MSC-heart interactions is the 
development of better in vitro model systems. Two-dimensional (2D) coculture of MSC 
and CFb relies on subjective interpretation of expression of ECM components and 
regulators to draw speculative conclusions about changes in stiffness. The most recent
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three-dimensional (3D) engineered tissue models allow investigation of survival, 
integration, differentiation, and coupling between stem cells and cardiac cells [6-8]. 
These models, however, are aimed at understanding how stem cells can help recover 
active contraction of cardiac tissue rather than modulating the passive stiffness. Prior to 
the work described in this dissertation, no model capable of directly coupling changes in 
stiffness with stem cell therapy has been described. The overarching purpose of the work 
described in this dissertation was to investigate the effects of MSC coculture with CFb 
mediated changes in stiffness. The objective of this work was accomplished through three 
distinct research phases:
1. Develop and characterize a 3D substrate capable of supporting and 
influencing fibroblast attachment and organization.
2. Design and validate a perfusion culture platform that supports a uniform 
fibroblast distribution throughout a 3D substrate of scalable thickness.
3. Apply the substrate and culture platform to evaluate MSC therapy on CFb- 
mediated changes in stiffness in vitro.
To provide a conceptual framework to this work, the physiologic role of the 
cardiac fibroblast, the impetus and mechanics of heart failure, cardiac cell therapy, and 
state-of-the-art cell culture and tissue engineering models are reviewed below.
1.2. The Cardiac Fibroblast
1.2.1 The Fibroblast in Cardiac Physiology
The human heart is a four chambered pump responsible for ensuring adequate 
metabolic exchange in our body. The primary function of the cardiovascular system is to
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convectively transport blood (and the metabolites it contains) throughout the body. The 
role of the heart in this system is to generate a pressure gradient that will move blood 
through the vasculature. Pulsatile flow is generated through a biphasic process consisting 
of filling (diastole) and emptying (systole) of the heart. During diastole, the pressure of 
the blood entering the ventricle is stored as strain energy in the ventricular wall as the 
ventricle stretches to accommodate an increased blood volume. Systole begins when the 
heart contracts. The active mechanical contraction of the heart can be described as a 
sudden and significant increase in the stiffness of the heart wall. The balance between the 
stress and strain of the tissue during diastole is no longer stable. The effectively stiffer 
tissue causes the ventricular muscle to contract to balance the stress with a proportionally 
smaller strain. The contraction of the heart is responsible for expelling a fraction of the 
blood and driving it through the body. The ejection fraction is a function of the difference 
between passive mechanical properties, and active mechanical contraction.
The majority of heart cells are either cardiac fibroblasts, or cardiac myocytes. 
Myocytes occupy the majority of the volume of the heart [9]. These cells are responsible 
for generation of active mechanical properties of the heart. Through an elegant 
excitation-contraction mechanism, electrical action potentials are converted to 
mechanical work -  shortening of the cardiac myocyte. Tissue organization and specific 
timing converts small contractions of individual cells to macroscopic tissue contraction.
The cardiac fibroblast is the other major cell type in the heart. Roughly 60-70% of 
all cells in the heart are fibroblasts [10]. These cells contribute to electrical, biochemical, 
and structural characteristics of cardiac muscle. Fibroblasts, unlike myocytes, are 
nonexcitable cells. They play a passive role in propagation of action potentials through
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cardiac muscle by acting as obstacles to the orderly spread electrical excitation in the 
heart. Recent discoveries have also implicated fibroblasts in a more active role in cardiac 
electrophysiology through gap junction connections with each other and cardiac 
myocytes [11, 12]. CFb also maintain the structure and composition of cardiac 
extracellular matrix (ECM). Type I and III collagen account for 90% of the protein 
content of the cardiac ECM [13]. The ECM helps mechanically couple myocytes, and 
transfers the force generated by individual myocytes throughout the organ [14]. 
Moreover, the ECM composition and organization provides the passive stiffness and 
toughness necessary during systole. Coordinated action of both myocytes and fibroblasts 
is necessary to maintain cardiac function. The following sections describe in further 
detail the role of the cardiac fibroblast in maintaining the structure and function of the 
cardiac ECM.
1.2.2 The Myofibroblast
In 1971, Gabbiani and colleagues observed what they termed a “modified 
fibroblast” and suggested that these cells have an important role in wound contraction
[15]. The distinguishing features of these cells included increased expression of an 
intracellular fibrillar system, nuclear deformations (due to contraction of the cell), and 
increased intercellular connections [15]. This modified type of the cardiac fibroblast has 
come to be known as the myofibroblast. The most discernible structural feature of the 
myofibroblast when compared to the fibroblast is the presence of smooth muscle actin 
and myosin. The distinction between CFb and the myofibroblast is significant in terms of 
activity. Cardiac fibroblasts have been referred to as “silent” under normal circumstances
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in the heart. The myofibroblast phenotype, on the other hand is typically associated with 
the active matrix synthesis, degradation, and modification activities normally associated 
with fibroblasts in general.
The transition to a myofibroblastic phenotype occurs in response in vivo to 
mechanical stimulation, hypoxia, and inflammatory cytokines [16]. In vitro, increased 
substrate stiffness has been shown to cause fibroblasts to assume a myofibroblastic 
phenotype [17]. Anseth and colleagues utilized a light sensitive hydrogel to demonstrate 
that myofibroblast differentiation is nonterminal, and can be reversed. Myofibroblasts on 
a relatively stiff hydrogel substrate were induced to deactivate by decreasing their 
substrate modulus [18]. Importantly, it has been hypothesized that increased stiffness in 
vivo due to fibrosis results in positive feedback, with more fibroblasts becoming activated 
and assuming the myofibroblast phenotype [19].
A specific definition of myofibroblasts as a different cell type has yet to be 
generally established. Indeed, fibroblasts are pleomorphic in the sense that they change 
their structure and function depending on external stimuli [10]. Therefore, in this work 
the myofibroblast will be considered a phenotypic subset of the fibroblast. In the section 
below, the fibroblast mediated mechanisms of ECM turnover are discussed. Elevated 
levels of ECM modification are typically associated with what is considered a 
myofibroblast phenotype.
1.2.3 Fibroblast Maintenance of the Extracellular Matrix
One primary physiologic role of cardiac fibroblasts (CFb) is to regulate 
extracellular matrix composition and properties through a complex network of interactive
6
7mechanisms. One of the important functions of the ECM is to maintain the passive 
stiffness and elasticity of cardiac muscle. Indeed it has been shown that ECM 
components, even in hypertrophic disease conditions, are almost entirely responsible for 
passive stiffness of the heart muscle [20]. CFb respond to chemical and mechanical cues 
that result in matrix synthesis, matrix degradation, and ECM modification. These tasks 
are accomplished through ECM component synthesis (primarily type I and type III 
collagen), expression of matrix metalloproteinases (MMP’s) and protease inhibitors 
(TIMP), and expression of matrix cross-linking enzymes enzymes (e.g., lysyl oxidases).
CFb are responsible for production of procollagen fibers that will eventually 
become type I and type III collagen, the primary dictators of passive cardiac stiffness
[21]. CFb synthesis of collagen is modulated through growth factors (e.g., TGF-P), signal 
peptides (e.g., angiotensin II), and cytokines (e.g., interleukins, TNF-a) [13]. The most 
potent regulators of collagen synthesis in CFb appear to be TGF-P, the rennin- 
angiotensin-aldesterone system (RAAS) and P-adrenergic system [22]. CFb also respond 
to mechanical stress by immediately increasing collagen deposition [16]. In vitro, CFb 
have been shown to increase matrix production in response to cyclic strain [23].
Another key role of the cardiac fibroblast is expression of matrix 
metalloproteinases (MMP). MMP are a family of zinc-dependent proteins expressed 
throughout the body. This class of proteases is responsible for cleaving extracellular 
matrix (ECM) molecules. In the heart, MMP play a critical role in maintaining the 
balance of ECM synthesis and degradation, as well as influencing ECM organization 
[24].
MMP are typically classified according to their substrate specificity. Cardiac 
fibroblasts express MMP-1, MMP-2, MMP-3, MMP-9, and MMP-14. Collagenase-type 
MMPs (MMP-1) cleave fibrillar collagen (type I, II, III). Gelatinases (MMP-2 and MMP- 
9) cleave gelatin, nonfibrillar collagen and fibronectin. Stromelysins (MMP-3), like 
gelatinases, can cleave gelatins, nonfibrillar collagens, and fibronectin; however, they 
also cleave laminin and MMP zymogens. This makes the stromelysin class of MMP 
important for regulation of other classes of MMP. The last class of MMP found in the 
heart are membrane bound proteases. MMP-14, a membrane bound MMP, has the same 
substrate specificity to stromelysins, plus fibrillar collagen. Cytokines (TNF-alpha, IL-1), 
growth factors (TGF-beta), signal molecules (angiotensin, endothelin), reactive oxygen 
species (ROS), and mechanical stimuli all affect MMP transcription.
MMP-1, 3 and 9 expression is typically low, and is upregulated by 
proinflammatory cytokines such as TNF-a and IL-6. MMP-2 and MMP-9 are expressed 
constitutively, however their expression can be increased by proinflammatory cytokines 
or decreased by angiotensin II through the TGF-P pathway. MMP-14 expression, 
remarkably, is increased by TGF-P expression. MMP-1 cleaves fibrillar collagen (types I,
II, and III) and MMP-1 expression has been shown to mitigate pathologic cardiac 
remodeling in transgenic mice [25]. Conversely, increased expression of MMP-2 has 
been associated with early (0-7 day) left ventricular rupture after infarction and late stage 
(4 week) dilatation in a murine MMP-2 knock-out model [26]. Increased expression of 
MMP-14 has also been shown to favor pathologic remodeling of the heart [27]. However, 
in a different murine model of heart failure, treatment with a proinflammatory nuclear 
protein 2 weeks after infarction increased the activity of MMP-2 and MMP-9. In apparent
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contradiction to previous findings, increased activity of MMP-2 resulted in higher 
ejection fractions and lower dilatation 7 weeks after infarction [28].
Because of the critical role of MMP in maintaining healthy, homeostatic condition 
of the ECM, they are tightly regulated not only in expression, but in function through a 
family of four different MMP inhibitors (TIMP). TIMP-3 is one of the major inhibitors 
found in cardiac tissue; it inhibits the function of all cardiac fibroblast-produced MMP. 
TIMP-3 is produced by most cardiac cells including myocytes, vascular smooth muscle 
cells, and fibroblasts. In addition to its function as an MMP inhibitor, TIMP-3 has MMP- 
independent effects including modulating Fb differentiation to myoFb, decreasing 
angiogenesis, signaling smooth muscle cell apoptosis, and preventing cardiomyocyte 
proliferation [29, 30].
Another fibroblast-mediated mechanism of ECM regulation in the heart is lysyl 
oxidase (LOX) production. LOX and LOX-like (LOXL) proteins are found throughout 
the body, including in the heart [31]. In the heart, LOX is an extracellular enzyme 
produced by CFb responsible for forming cross-links in types I and III fibrillar collagen. 
Crosslinking is the final step in collagen synthesis, and results in collagen fibrils that are 
less soluble, more resistant to degradation, and much stiffer [32]. LOX expression is 
stimulated through hypoxia and TNF-a (mediated through TGF-P signaling) [33].
The last, and indirect method of CFb maintenance of the ECM is through cellular 
signaling. Fibroblasts, in response to angiotensin II, increase production of TGF-P which 
in turn act as a potent autocrine signal for ECM modulation [34]. Further, CFb are the 
primary source of tumor necrosis factor-a (TNF-a) which serves as both an autocrine 
signaling molecule for fibroblast activity, and a paracrine signal molecule for numerous
9
other cell types [35]. Interleukin-6 (IL-6) is another CFb-produced molecule that 
influences cell activity in the heart [36]. In response to proinflammatory cytokines, 
human CFb has been shown to upregulate expression of cell surface markers such as 
ICAM-1 and E-selectin that facilitate leukocyte recruitment [37]. These cells in turn, 
express ROS that enhance the function of LOX.
Until recently, the focus on cardiac tissue has been on the elegant excitation 
contraction mechanism of cardiac myocytes. Fibroblasts have been relegated to bystander 
status with little appreciation given for the role they play in maintenance and support of 
the myocardium. We are now beginning to understand just how important fibroblasts are 
in the production, maintenance and remodeling of the cardiac ECM. Myocytes play little 
role in the ECM synthesis and architecture yet rely on this matrix to act in synchrony to 
develop a functional contraction to pump blood through our vasculature. Understanding 
the role that fibroblasts play in creating and maintaining the exquisite balance of 
mechanical properties needed for optimum cardiac performance is paramount for the 
development of regenerative strategies for cardiac repair.
1.2.4 Fibroblast Contributions to Biomechanical Stiffness
Fibroblasts are the most numerous stromal cell type in the heart. Fibroblasts have 
been shown to contribute to tissue stiffness through two different mechanisms: directly 
through tractional forces including cytoskeletal filament contraction [38] and indirectly 
through expression and assembly of matrix elements. Here both contributions of 
fibroblasts to the biomechanical stiffness of 3D tissue will be reviewed.
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Some of the earliest studies investigating cell tractional forces were performed in 
collagen gels. Bell and colleagues developed a unique 3D model of dermal fibroblast (Fb) 
behavior by casting living fibroblasts inside a collagen gel [39]. They observed six to 
eight fold decreases in collagen expression in 3D collagen matrices when compared to 
2D culture conditions. Further, the collagen that was produced in the 3D model appeared 
to be tightly bound to the surrounding matrix while collagen produced in 2D culture was 
passed to the culture medium [40]. In addition, they observed that upon incorporation 
into the gel lattice, fibroblasts began to extend processes and collect collagen fibrils. This 
compaction of collagen resulted in macroscopic contraction of the collagen gel [41]. 
Grinnell and colleagues modified this model to evaluate fibroblast mediated contraction 
of collagen gels. They utilized either floating, unconstrained collagen gels, or 
mechanically anchored gels to evaluate fibroblast mediated contraction of the gels [42]. 
Floating gels were unstressed throughout the experiments, while anchored gels developed 
internal stresses. Two different mechanisms of contraction of the gels were observed; in 
unstressed gels, tractional forces resulting from extension of Fb processes was 
responsible for contraction. Moreover, in unstressed gels, the fibroblasts maintained a 
dendritic morphology and did not produce high level of actin stress fibers [43]. In 
contrast to their behavior in unstressed gels, Fb in stressed gels were observed to elongate 
into a lamellar phenotype expressing higher levels of smooth muscle actin filaments [44]. 
Upon release of the gel, these cells also were observed to contract the collagen gel. 
Although the outcome of gel contraction was identical, the difference in Fb response to 
the two conditions indicated the possibility of a different mechanism responsible for each 
condition. Indeed it was observed that contraction of unstressed collagen is primarily due
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to extension of cellular processes that create tractional forces, while contraction of 
stressed gels results from smooth muscle-like contraction of the Fb themselves [45]. 
Grinnell further demonstrated the difference in these mechanism by showing that 
contraction can be induced in floating gels by platelet derived growth factor (PDGF) 
stimulation, while contraction in the stressed state is not induced by PDGF [46]. 
Coupling cell-populated collagen gels to strain gauges in order to measure cell tractional 
forces allowed assessment of tractional force, however this approach is limited to 
measuring bulk forces, and cannot assess the contribution of individual cells [38].
Elegant methods for measuring individual cell tractional forces (CTF) have been 
developed to understand the forces that can be generated by fibroblasts to complement 
the work that was performed using cell-populated collagen gels. In 1980, Harris et al. 
described a method of culturing cells on a thin polymer film and observing wrinkling of 
the film as a measure of CTF [47]. This method was improved by anchoring the edges the 
silicone film, and incorporating fiduciary beads. The embedded beads allow 
quantification of surface deformation, and therefore permit estimation of the CTF with 
force resolution approaching nanonewtons [48]. The elasticity of the silicone film in 
conjunction with the surface deformation can be used to create a surface force map. An 
alternative to the use of silicone films is the use of polyacrylamide gels [49]. Mircobead 
markers embedded in the gel provide deformation data, while the concentration of 
acrylamide determines the stiffness of the gel. The low affinity of cells for 
polyacrylamide gels requires gel coating with ECM proteins such as fibronectin to allow 
mediate cell attachment. Use of micromachined force sensors is another approach to
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measuring CTF. Du Roure and colleagues developed a micropost array that is able to 
measure post deformation and correlate the deformation directly to cellular forces [50].
In addition to the potential for active contraction, cardiac stromal cells contribute 
to stiffness of cardiac tissue through expression and assembly of matrix elements as 
described in the previous section. Collagen (primarily type I and type III) is the 
predominant constituent of cardiac extracellular matrix. By volume, it comprises 2-6% of 
the myocardium [51]. Despite the low volume fraction, collagen appears to be the 
primary contributor to myocardial stiffness due to its relatively high modulus. The 
modulus of a single procollagen molecule ranges from 2.9 to 9.0 GPa as measure using 
an X-ray diffraction technique [52]. Once assembled into macroscopic filaments, 
collagen fibers are considerably softer, measured at 0.7-3.7 MPa using tensile stress- 
strain analysis [53]. Collagen fibers are coupled to the cells themselves through lateral 
struts that are anchored through focal adhesion complexes [54]. Confocal microscopy has 
revealed that interstitial collagen fibers in the relaxed heart resemble a helical twisted 
ribbon with relatively high degree of tortuosity [55]. During diastole as the myocardium 
is strained, it appears that perimysial collagen fibers are not elongated, but rather undergo 
helical bending and uncrimping. The energy required to bend and uncrimp the collagen 
appears to accounts for the majority of the measured stiffness in the myocardium [56]. In 
a mathematical model of cardiac tissue these forces have been calculated to be on the 
order of 135-160 MPa [56] which correspond to roughly 100% of the modulus measured 
in rat ventricular tissue [57].
In the model described in this research, Fb are grown on a non-degradable, elastic 
polyurethane substrate. The goal of the research to evaluate tissue-level changes in
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passive stiffness, so while this model as described in this work cannot discriminate 
between individual contributions of cells and matrix, it can provide an overall functional 
picture of changes in tissue stiffness. In reality, the overall changes in stiffness measured 
in this model are a composite value corresponding to contribution of both active cell 
tractional forces, and passive matrix stiffness.
1.3. Cardiac Disease and Heart Failure
1.3.1 Cardiac Disease
Heart disease is a leading cause of death worldwide [58]. In America, an average 
of 2,300 people died every day from cardiovascular disease in 2006 [1]. Many 
cardiovascular diseases including infarction, hypertension, valvular diseases, and 
congenital heart disease lead to the same end stage outcome: heart failure [59]. Heart 
failure is currently only treatable with transplant and has a high associated mortality. 
Moreover, heart failure is a chronic condition that constitutes a major socio-economic 
burden to nations, and a significant personal burden to families and individuals. Rates of 
heart failure are increasing in developed countries due to longer life-spans and increased 
likelihood of surviving of acute myocardial injury (primarily infarction) [22].
Heart failure occurs when the cardiac output is unable to meet the metabolic 
demands of the body. There are two mechanisms of heart failure: systolic and diastolic
[60]. Systolic heart failure occurs when the heart is unable to generate sufficient force to 
eject all of the blood from the heart. Ejection fraction is typically decreased during 
systolic heart failure. Systolic heart failure results from decreased efficiency of cardiac 
contraction. Ischemia/infarction can cause myocyte necrosis and apoptosis, which may
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contribute to systolic HF. The primary impetus, however, for systolic HF is expansion of 
the dilatation of the ventricular chamber which increases wall stresses and creates further 
stress on functional myocytes [22].
Diastolic heart failure, on the other hand results from inadequate filling of the 
ventricle. This is almost exclusively a result of fibrosis, which in turn is a secondary 
effect of a primary cardiac pathology. During diastolic heart failure, increases in stiffness 
of the cardiac muscle prevent adequate filling of the ventricle during diastole. So while 
ejection fraction may remain high, cardiac output is decreased.
Both systolic and diastolic heart failure are results of maladaptive structural 
remodeling of the heart. While there are many cardiovascular diseases that share HF as 
an end-stage outcome, here only HF induced through coronary artery disease and 
myocardial infarction is addressed.
1.3.2 Maladaptive Remodeling
Studies of the biomechanical response of the left ventricle (LV) to myocardial 
infarction (MI) have identified infarct expansion (i.e., stretching) and infarct-induced 
fibrosis of remote tissue as important phenomenon that both initiate and sustain a 
progressive pathologic process that ultimately results in structural and functional changes 
of the heart [61, 62]. This maladaptive response is a complex biomechanical process 
caused by depletion of myocytes from the infarct zone and a biologic response to 
abnormal stress distributions in the heart [63]. Clinically, ventricular remodeling is a 
primary indicator of adverse outcomes such as chronic heart failure and death [64].
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Within minutes to hours of ischemia-induced hypoxia, cellular death occurs and 
cardiac tissue ceases to be an active, force-generating tissue, and assumes passive 
viscoelastic mechanical properties [65]. Systolic stiffness of the infarcted tissue is 
decreased drastically. During this phase, the tissue begins to be depleted of its myocyte 
population through necrosis (20% of cells) and apoptosis (80% of cells) [66]. 
Simultaneously, the disparity between the systolic stiffness of the unimpaired heart and 
infarcted region results in dyskinesis and stretching of the infarcted region [67]. This 
mismatch in stiffness dissipates the mechanical energy generated by the contractile 
region of the heart, resulting in decreased ejection fraction (EF). Stroke volume is 
maintained by increasing the end diastolic volume (EDV), and results in long-term 
cardiac dilatation. However, cardiac dilatation further increases the burden on functional 
myocytes through increased wall stresses according to Laplace’s law [63]. Moreover, it is 
during this acute phase prior to infarct stiffening through neomatrix formation that the 
risk of catastrophic failure resulting from rupture of the ventricle is highest [61]. A rapid 
increase in the passive stiffness of the infarcted tissue is imperative for maintaining 
cardiac function.
Within hours, the passive (diastolic) stiffness of the tissue begins to increase due 
to edema [65]. In an ovine model of MI, passive stiffness of infarcted tissue increased by 
approximately 250% after 4 hrs [68]. At about 1 week postinfarction in humans, the 
fibrotic phase begins resulting in accumulation of collagen produced by activated 
myofibroblasts. This local deposition of collagen results in significantly increased 
stiffness of the infarct. In the previously mentioned ovine model, the passive stiffness 
increased by 800% at 1 week post-MI, and 1600% at 2 weeks [68]. This increase in
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stiffness is critical for minimizing infarct expansion, decreasing the risk of rupture, and 
restoring ejection fraction by decreasing the energy loss due to infarct stretching. Indeed 
insufficient stiffening of the infarcted region results in infarct expansion, wall thinning, 
and dilatated cardiomyopathy; all of which are predictive factors pointing toward systolic 
heart failure [61]. While stiffening of the infarcted region is critical for prevention of 
maladaptive remodeling, it is a double-edged sword. Stiffening of the infarct has been 
associated with stiffening of regions remote to the infarct as well. Gupta et al. showed 
that in the ovine model of MI, the passive stiffness of the remote myocardium had 
increased >300% at 1 week [68]. Using a rabbit model of hypertension-induced heart 
failure, Yamamoto et al. demonstrated that changes in the passive stiffness of cardiac 
tissue are due to fibrosis, rather than compensatory hypertrophy of the myocyte 
population that is associated with both hypertensive and MI induced heart failure [20]. In 
a sheep model of MI, Wilson et al. demonstrated that matrix metalloproteinase (MMP) 
and tissue inhibitors of metalloproteinases (TIMP) levels in the remote regions were 
altered compared to control values indicative of ECM remodeling remote to the infarct
[69]. Accumulation of collagen in sites remote to the infarct results in pathologic fibrosis, 
and increased passive stiffness of the myocardium which in turn causes decreased EDV 
of the heart, decreased cardiac output, and diastolic heart failure.
It is clear that changes in active and passive mechanical properties of both the 
infarct and noninfarcted myocardium are key parameters affecting ventricular remodeling 
and corresponding health outcomes after MI. During the early stages after MI it is 
essential to have a significant increase in passive stiffness of the infarcted zone. 
However, in later stages, increased fibrosis in the infarct leads to remote matrix
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accumulation, global stiffening of the heart, pathologic fibrosis, and diastolic heart 
failure.
1.3.3 The Role of the Cardiac Fibroblast in Remodeling
Cardiac fibroblasts are jointly responsible with acute phase inflammatory cells for 
wound healing after cardiac injury. The successful recapitulation of cardiac function after 
the initial insult is largely dependent on the activity of CFb. Upon infarction, inactive 
MMP found in the interstitial space become are zymogenically activated as surrounding 
matrix is degraded in response to necrotic and apoptotic signals from myocytes. This 
immediate activation results in a local and significant degradation of collagen. Takahashi 
et al. demonstrated that within 3 hrs after infarction, 50% of collagen in the infarct region 
was degraded in rats [70]. Increased MMP activity and resultant decreases in the collagen 
volume fraction in the heart have been correlated with ventricular dilatation and systolic 
dysfunction [71].
Collagen cross-linking is another important factor that impacts cardiac function. 
Fibroblasts affect collagen cross-linking through LOX production and secretion. While it 
has been shown that collagen production increases in the infarct region [72], this does not 
necessarily translate to an increase in tissue stiffness (see [68]). Several studies have 
correlated increases in collagen cross-linking with increases in apparent myocardial 
stiffness [73, 74]. These increases in apparent myocardial stiffness, and not just collagen 
content are hypothesized to be responsible for diastolic dysfunction of the heart.
The passive stiffness of the myocardium is paramount in determining post-MI 
outcomes. Scar formation in myocyte depleted regions is a dynamic process consisting of
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continuous collagen turnover, cytokine expression, and myofibroblastic activation 
persisting in humans for decades [75]. ECM and therefore the cardiac fibroblast clearly 
have an important role in maintaining the geometry and elasticity of the heart in both the 
acute and long term after infarction. Improved understanding of the mechanisms 
responsible for fibroblast-mediated changes in stiffness will provide a foundation for 
novel therapeutic approaches to treating heart failure.
1.4. Cardiac Cell Therapy
Under normal conditions after MI, myocytes are depleted from the wound site via 
necrosis or apoptosis. Fibroblasts replace the missing myocytes with a stiff, dense scar. 
Little regeneration of cardiac muscle occurs. Chronic mechanical stimulation and 
autocrine signaling through TGF-P and TNF-a results in maladaptive remodeling and 
heart failure initiated by changes in ventricular fibroblast activity. Starting around the 
year 2000, a novel approach to regenerating cardiac muscle began to be explored: cardiac 
cell therapy.
The complex biologic and mechanical impetus of ventricular remodeling makes it 
a challenging pathology to treat. Indeed, medical device and pharmacologic treatments 
are used to manage and minimize cardiac remodeling, but are generally unable to reverse 
its course [62]. Heart transplantation remains the most effective method for treating 
maladaptive remodeling, but is limited by a persistent shortage of donor organs. Cardiac 
cell therapy is a promising new treatment that is currently in the early phases of clinical 
trials [2, 76]. In a single case study performed by Okano and colleagues, a myoblast 
“cell-sheet” was delivered to a patient with progressive heart failure. After implantation,
this treatment improved the patient’s EF from 26% to 46%, allowed explantation of his 
left ventricular assist system, and removed him from the heart transplant waiting list [77].
Cell therapy utilizes exogenous cells to stimulate cardiac regeneration. Early 
attempts to regenerate cardiac function focused on delivering cells that would replace the 
myocytes lost to ischemic injury. In the last 12 years, however, the cardiac cell therapy 
paradigm has shifted largely away from replacement of myocytes, to cytoprotective and 
regenerative paracrine support of cardiac function [66, 78]. Utilization of mesenchymal 
stem cells (MSC) in animal models, has shown considerable promise as a treatment to 
prevent postinfarction remodeling. Moreover, the low immunogenicity of MSC allows 
the use of allogenic donor cells and proprietary expansion methods of MSC make this 
cell type attractive to biotech companies interested in commercialization [5].
In small animal models of MI, MSC have been shown to effectively treat some of 
the major histologic and functional pathologies associated with ventricular remodeling. 
Mias et al. showed that in a rat MI model, injection of MSC pretreated with melatonin 
significantly increased ejection fraction (EF), and decreased wall thinning and collagen 
accumulation [4]. Godier-Furnemont and colleagues utilized a decellularized human 
tissue patch to deliver TGF-P pre-conditioned mesenchymal precursor cells to a nude rat 
MI model [79]. Histologically, they observed increased angiogenesis; functionally, they 
observed increased fractional shortening (FS) of the heart. Another group genetically 
modified MSC to increase prostaglandin I synthase (PG1S) transcription. Increased PG1S 
production resulted in increased FS and EF, while simultaneously decreasing fibrosis, 
wall thinning and apoptosis [80]. Gnecchi et al. showed that MSC’s modified with ATK-
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1, a cytoprotective factor encoding gene, were shown to result in smaller infarct sizes and 
decreased myocyte apoptosis after infarction in rats [81].
Despite the numerous animal studies performed, and their favorable results, the 
mechanism behind the observed efficacy of cell therapy in animal models is still poorly 
understood. There are, in fact, at least five proposed paracrine mechanisms that may be 
responsible for the histologic and functional improvements observed in animal studies:
(1) Decreased remodeling of the myocardium, (2) paracrine mediated angiogenesis, (3) 
modulation of the immune response, (4) cytoprotection of residual myocytes in the 
infarct region and border zones, and (5) recruitment of resident cardiac progenitor cells 
[82-85]. This lack of mechanistic understanding becomes significantly more important 
when the results of early human clinical trials are considered. Unlike most animal 
models, the efficacy of cell therapy in humans has been questionable. A meta analysis of 
13 clinical trials with a total of 811 patients revealed that bone marrow cell therapy did 
not improve postinfarction remodeling [5]. Further mechanistic investigation of cell 
therapy is paramount for moving cell therapies from the trial phase to a standard 
treatment in the clinic.
Certain approaches to cell therapy have proposed that the fibroblast may be an 
important therapeutic target for cell therapy. Mias et al. showed that fibroblast MMP 
expression was altered by paracrine factors from injected MSC [4]. While this study is 
key, there is no direct link between the expression of MMP and mechanical properties, 
which are more directly responsible for the function of the heart. Development of a 
model that couples changes in bulk mechanical properties based on cell injection
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approaches will accelerate our ability to design cell-based therapies that more effectively 
prevent maladaptive remodeling of the heart.
1.5. Three-Dimensional Cell Culture Models
In vitro cell culture is a common tool used to evaluate the response of cells to 
stimuli. Practically, cell culture is an essential component of all drug and device 
development. Indeed ISO 10993 -  the international standard for medical device 
biocompatibility -  requires that cell culture be used to evaluate cytotoxicity for all 
medical devices adhering to this standard. The primary components of cardiac cell 
culture strategies are: (1) the substrate, (2) the environmental culture conditions, (3) the 
culture medium, and (4) the cells themselves [86]. Since the first attempts at cell culture, 
researchers have been defining and refining these elements of cell culture. Current tissue 
culture plastic (TCP) based cell culture models are the result of decades of discovery and 
development.
In more recent history, focus has shifted from development of cell culture models 
that are cultured on a flat substrate like TCP, to development of three-dimensional (3D) 
cell culture models [87]. This has been a particularly challenging paradigm shift to 
implement, because both the substrate and the culture conditions must change drastically 
to accommodate 3D cell culture. This section will review some of the key developments 
in substrate design, and culture platform innovation that have facilitated development of 
3D models. Further, recent applications of 3D tissue models to understanding cardiac cell 
therapy will be reviewed.
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1.5.1 The Substrate
Cardiac cells, including fibroblasts, are anchorage-dependent, and therefore 
require a substrate for attachment to facilitate survival, activity, and proliferation. In the 
realm of tissue engineering there are currently four different approaches to providing a 
3D substrate: (1) utilization of naturally occurring substrates from animals, (2) cell 
entrapment within hydrogels, (3) lamination of cell sheets with a self-assembled 
substrate, and (4) utilization of porous, engineered substrates [88-90]. Each of these 
approaches provides engineering control over two key substrate properties: (1) material 
composition (2) substrate microarchitecture, including porosity, alignment, and 
mechanical properties.
1.5.1.1 Material Composition
Evaluation of cardiac fibroblast (CFb) response to material composition in the 
literature is very limited. Exclusive cardiac fibroblast culture in 3D substrates are almost 
nonexistent. Most studies that have cultured CFb on different materials have included the 
CFb as part of a coculture including myocytes. Lasher et al. utilized fibrin gel to 
coculture cardiac myocytes and cardiac fibroblasts [91]. Vimentin staining revealed 
cardiac fibroblasts distributed between myocytes throughout the construct. These findings 
indicate that CFb are able to maintain vitality when cultured in serum containing DMEM- 
based media. Moreover, electrical stimulation did not appear to affect CFb numbers [91]. 
Freed et al. evaluated CFb cultured on a synthetic, elastomeric polymer substrate. Her 
group stained for F-actin in a mixed neonatal rat heart cell population. They observed that 
F-actin expressing cells (primarily CFb) filled the void spaces in porous poly (glycerol-
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sebacate) substrates [57]. Our own group demonstrated that cardiac fibroblasts will attach 
and proliferate on poly (ether-urethane) substrates in serum containing media (See 
Chapter 3). Further we observed that cell attachment after perfusion seeding significantly 
increased with a composite fibronectin-coated polyurethane substrate (unpublished data).
1.5.1.2 Architecture
Substrate microarchitecture profoundly influences cell response to the substrate. 
Further, substrate microarchitecture can be used to influence functional properties of the 
tissue model such as stiffness and hydraulic permeability. The geometric configuration of 
the substrate on the micro scale is determined by material fabrication and processing 
techniques. Therefore, a discussion of substrate design parameters must necessarily be 
coupled with a discussion of fabrication methods and techniques. The key architectural 
features that will be discussed here are: (1) porosity, (2) alignment/anisotropy, (3) 
stiffness, and (4) hydraulic permeability.
1.5.1.2.1 Porosity. Porosity is defined as the ratio of void space to total volume of 
a porous material. This parameter affects how much space is available for cells to occupy, 
diffusion of nutrients through the substrate matrix, and the effective mechanical 
properties of the construct [92]. Techniques for evaluating porosity include mercury- 
intrusion porosimetry, optical analysis, and gravimetric analysis (based on material 
densities). These methods provide insight to pore size, pore morphology, and porosity 
respectively. Electrospinning is common biomaterial fabrication technique for creating 
fibrous, nonwoven materials with fiber diameters typically on the order nanometers [93]. 
A polymer dissolved in solution is drawn through a charged spinneret to a conductive
surface by a high electrical potential, typically on the order of 10 kV [94, 95]. Baker et al. 
utilized an electrospinning approach to prepare fibrous of controlled porosity [96]. 
Sacrificial poly (ethylene oxide) (PEO) fibers were cospun with permanent poly (s- 
caprolactone) fibers. After spinning, the PEO fibers were removed by ethanol immersion 
for 3 hrs, resulting in increased porosity that was dependent on the fraction of PEO fibers 
in the original material. Cell culture studies revealed that cell infiltration into the interior 
of the 3D substrate increased with increased fraction of sacrificial fibers [96]. Phase 
separation is a technique that is frequently used to fabricate porous biomaterials. This 
fabrication technique provides significantly more flexibility to the ability to control 
porosity of the resultant material. Rowlands et al. used a thermal phase separation (TIPS) 
technique to form polyurethane/PLGA substrates with pores ranging from 0.1-200 p,m in 
diameter [97]. Woodhouse and colleagues created porous polyurethane substrates using 
TIPS. The resultant material was found to have nominal porosities ranging from 14% to 
35% depending on fabrication conditions. When embryonic stem cell-derived cardiac 
cells were seeded onto these substrates, they were observed to infiltrate approximately 72 
p,m into the tissue, with significantly decreased numbers beyond this depth [98]. Another 
variant to the phase separation approach is the sprayed technique. In sprayed phased 
separation, two spray nozzles are simultaneously employed to deposit a solvent solution 
and nonsolvent onto a surface. Khorasani et al. described an elegant sprayed phase 
separation technique where porous substrates were fabricated by spraying onto a rotating 
mandrel. SEM was used to evaluate morphological changes that occurred in response to 
changes in the working distance of the spray nozzles and the speed of the mandrel [99]. 
Papenburg et al. took the phase separation fabrication techniques a step further. They
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introduced a notable micromolding enhancement to the phase separation approach. This 
method utilizes a patterned substrate to provide geometric patterns to a thin sheet of 
phase separated material [100]. Moreover, they investigated the use of several different 
alcohols as nonsolvents in substrate formation. They determined that the type of alcohol 
affected porosity and pore structure. Using this method, they were able to independently 
control surface patterns of thin sheets through the mold geometry, and porosity through 
variation of the composition of the nonsolvent [100]. In addition to these approaches, 
Papenburg and colleagues also proposed, simultaneously to my own research, lamination 
of thin phase separated sheets to build thick 3D constructs [101].
Control over porosity has evolved from simple use of sacrificial components, to 
elegant physiochemical-control mechanisms that provide multiple levels of input and 
capabilities to substrate fabrication techniques. The work described herein utilizes a 
sprayed phase separation approach to substrate fabrication because of the high level of 
control over porosity and the ease of automation of this approach.
1.5.1.2.2 Alignment. Substrate alignment is a key feature that relates both to cell 
response and bulk mechanical properties. Contact guidance is a well established 
hypothesis that postulates that cells will be guided through contacting external geometric 
cues [102]. Using advanced quantification techniques [103], Freed and colleagues 
demonstrated that cardiac fibroblasts would align according to geometric cues of laser- 
ablated synthetic substrates [57]. Using micromolding techniques, Papenburg et al. 
demonstrated that cells can be aligned according to CAD-defined geometric patterns
[100]. In Chapter 3, utilization of postspray elongation technique is discussed in detail
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that provides alignment cues to fibroblasts. Further, a FFT-based method for assessing 
cellular alignment in response to the substrate is described.
1.5.1.2.3 Mechanical properties. Substrate mechanical properties are often key 
determinants of construct function. In addition, substrate mechanical properties can have 
profound effects on cellular activity [17, 104]. For soft tissue (such as cardiac tissue) 
tensile properties are of primary interest. In general, mechanical properties are measured 
through tensile testing, and normalization of the results. Cardiac tissue is a highly 
anisotropic tissue, meaning that, structural and functional parameters are inhomogeneous. 
Tensile properties of cardiac tissue are generally referred to in terms of the longitudinal 
or preferred modulus, and the transverse modulus. Several approaches to recapitulating 
the anisotropy of cardiac tissue in biomaterial substrates have been proposed. One 
method for controlling mechanical properties of cell substrate is through material 
composition. Zhang et al. developed custom polyurethane base formulations, and 
demonstrated different tensile properties over time base on material composition [105]. 
Rowlands et al. utilized different blends of polyurethane and PLGA, and demonstrated 
moduli ranging from 15 to 93 kPa depending on the material composition [97]. 
Geometric composition is another approach to control mechanical properties. Baker et al. 
achieved anisotropic geometry by electro-spinning onto a rotating mandrel to create fiber 
alignment. This fiber alignment resulted in an approximately 10-fold difference between 
the elastic modulus in the preferred direction and transverse direction [96]. Moroni et al. 
utilized a 3D fiber deposition approach controlled by CAD-CAM techniques to create 
substrates with geometrically controlled moduli ranging from 0.26 MPa to 13.7 MPa 
[106]. In Chapter 3, a postspray elongation technique is used to create geometric base
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tensile anisotropy. This anisotropy is evaluated both optically through electron 
microscopy, and mechanically through tensile testing.
1.5.1.2.4 Hydraulic permeability. The last architectural feature of biomaterial for 
substrates that will be discussed here is hydraulic permeability. Hydraulic permeability is 
defined as the permeability of a porous medium to aqueous solutions. This architectural 
feature is of special interest to 3D cell culture because media perfusion is often used to 
enhance mass transport in the interior of thick substrates. Hydraulic permeability is 
measured by monitoring flow of media through a substrate while maintaining a constant 
head pressure. Hydraulic permeability, like mechanical properties, can be either isotropic, 
or anisotropic. Geometric features such as channels can be included in the porous matrix 
to influence hydraulic permeability [107-109]. Papenburg et al. utilized the micromolding 
approach to design corrugations into thin sheets which were then rolled up resulting in 
channel-like geometries running through the materials [110]. Chapter 4 includes a 
detailed discussion hydraulic permeability of various types of substrates including the 
substrate developed for use in this work.
1.5.2. Culture Conditions
Advances in design, processing, and fabrication of 3D substrates has necessitated 
concurrent advances in cell culture platforms. Native human tissue is sustained through a 
complex cooperation between multiple physiologic systems. As engineered tissues 
become more complex, the framework required to support the tissue will increase in 
complexity. Engineered tissue that is identical to native tissue will, by definition, require 
the same type of complex environmental support that is found in the body. The design of
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advanced bioreactors and culture conditions is an essential step toward achieving more 
native like tissues.
In an important review, Barron et al. defines a bioreactor as “a system that 
simulates physiological environments for the creation, physical conditioning, and testing 
of cells, tissues, precursors, support structures, and organs in vitro” [111]. In the realm of 
cardiac tissue engineering, there are three important environmental conditions that can be 
simulated through utilization of bioreactors: mechanical stimulation, electrical 
stimulation, and enhanced metabolic exchange through perfusive flow [111]. In addition, 
an essential function of a bioreactor for evaluating 3D cardiac tissue is to support a 
uniform cell distribution throughout a 3D substrate [112, 113].
The greatest impediment to obtaining a uniform cell distribution in a 3D model is 
maintaining proper mass transport. Oxygen, nutrients, and metabolites must be brought 
near enough to cells to allow diffusive transport to exchange the spent resources with 
fresh ones. Convective fluid transport is the most versatile way of supplementing the 
transport capabilities of diffusion. Without convective supplementation, diffusion can 
only provide support to cardiac tissue that is ~100 p,m thick [114]. In a mathematical 
model of oxygen transport and consumption, Radisic et al. demonstrated that perfusion of 
a channeled substrate can provide sufficient oxygen to support a 2 mm thick construct 
that is densely packed with cardiac cells [115]. In an in vitro model, Carrier et al. 
demonstrated that perfusion increased spatial uniformity of cardiac cells in a synthetic 3D 
substrate [116]. Liu and colleagues demonstrated that perfusion significantly increased 
the number of cells on an elastomeric polyurethane substrate when compared to static 
controls [117]. Moreover, perfusion provides important stimuli to cardiac cells. Maidhof
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and colleagues showed that excitation threshold increased significantly without perfusion 
or electrical stimulation [118].
There are two distinct phases that occur during perfusion culture that influence 
cell distribution: seeding and steady state culture. The seeding phase of culture occurs in 
the beginning to help cells attach to the substrate. In a 3D substrate, efficient seeding is 
necessary to ensure that cells are anchored uniformly throughout the material. Maidhof et 
al. explored the important seeding parameters in elastomeric channeled substrates. They 
determined that flow velocity and duration of seeding of cardiac myocytes are important 
seeding parameters [108]. They evaluated seeding velocities ranging from 6 mm/min to 
60 mm/min. They determined the highest flow (60 mm/min) resulted in the highest 
seeding efficiency (87%). When they investigated how long to maintain the seeding 
velocity, they found that 2 hrs provided a higher seeding efficiency than 1 hr. During the 
steady state culture phase, the flow velocity is the primary perfusion parameter. McCoy 
et al. developed a mathematical model to understand the effect of flow rate on cell 
attachment in a bioreactor [119]. Under high flow conditions, cells were detached from 
the substrate surface by the flow-induced shear stress. The work of McCoy et al. and 
Maidhof et al. help establish general constraints for seeding and steady state perfusion 
parameters: high velocity is good for a limited duration while cells are attaching, but 
lower velocities are better long term to prevent cells from detaching.
1.5.3 3D Cell Culture Applications
3D cell culture is only possible through the use of appropriate substrates and 
culture platforms. Development of 3D culture techniques, while challenging, has been
primarily motivated by two different potential applications: therapeutic use of 3D cell 
culture (engineered tissue) to treat diseased or damaged tissue [88, 120, 121], and 
utilization of advanced cell culture as a bridge between 2D in vitro and in vivo testing 
[87, 122, 123].
Many of the design requirements for engineered tissue and 3D models overlap, 
however, there are fundamental differences. For example, cell culture models do not have 
the stringent requirements for systemic biocompatibility that are necessary for implanted 
tissues. While this can simplify some aspects of the design, the advantage is tempered by 
inability of in vitro models to undergo modification after implantation. For example, one 
approach to creating therapeutic engineered tissue relies on in vitro angiogenesis to 
provide vascularization [124, 125]. 3D models, on the other hand, will undergo 
angiogenesis and vascularization only if the culture conditions are designed specifically 
for this purpose.
At the present, there has been only one attempt at developing 3D cardiac 
fibroblast models. Gaile et al. seeded CFb into collagen gels that were either free floating, 
or constrained at the edges and observed changes in mRNA levels of collagen (type I and 
III), TGF-P, and a-smooth muscle actin (a-SMA) [17]. No changes in collagen or TGF-P 
expression were detected. A significant increase in a-SMA was detected at 6 and 24 hrs, 
but became nonsignificant after 48 hrs. Further Gaile and colleagues monitored the 
stiffness of the constructs after 6 hrs and 120 hrs. They noted that the elastic modulus was 
similar to fibrotic cardiac tissue after 120 hrs and proposed that a 3D cell model of 
cardiac fibroblasts could be used to better understand fibrosis in the heart [17].
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While engineered tissue models have primarily been focused on cardiac 
myocytes, some models have been developed that utilize a mixed cell population of both 
myocytes and fibroblasts. Freed and colleagues demonstrated that coculture of myocytes 
and CFb resulted in higher levels of MMP 2 expression than CM enriched populations 
[126]. In another study, Freed and colleagues observed that cardiac fibroblasts when 
cocultured with myocytes aligned to match scaffold geometry [57].
Beyond the scope of cardiac fibroblasts, the concept of a 3D in vitro model for 
evaluating stem cell therapy has been pioneered by Radisic and colleagues [6]. Using a 
collagen sponge substrate and an electrical stimulation bioreactor, Song et al. investigated 
the functional integration of injected stem cells and surrogate heart tissue. They observed 
that embryonic stem cell derived cardiomyocytes (ESC-CM) cultured in low glucose 
were able to significantly improve the excitation threshold of the surrogate cardiac tissue
[7]. On the other hand, these same cells also decreased the maximum rate of synchronous 
contraction of these constructs. In another important study, Radisic’s group used 
surrogate cardiac tissue to understand embryonic stem cell (ESC) response to a cardiac 
environment [8]. They observed that ESC can survive and even proliferate in a cardiac 
environment. Despite this initial positive finding, they also observed that ESC did not 
functionally integrate with the surrogate heart tissue. The findings of these landmark 
studies have pushed researchers to look for other potential mechanisms of cardiac 
regeneration through cell therapy, and demonstrate the utility of 3D cell models in 
evaluating and designing stem cell therapies.
The last type of in vitro 3D model that will be discussed here is explanted cardiac 
tissue models. Pillenkamp developed a model of cardiac tissue by explanting and
32
sectioning murine hearts. These 300 p,m thick slices of cardiac tissue were functionally 
maintained using static cell culture techniques for up to 24 hrs before evidence of 
apoptosis became evident [127]. These models were used to assess the influence of ESC- 
CM injection on force of contraction of the tissue [127]. The results indicated that ESC- 
CM injection improved contractile force of the constructs. Pillenkamp et al., like 
Radisic’s group, observed that ESC-CM did not functionally integrate with surrounding 
cardiac tissue [128]. Another group modified the tissue slice model by utilizing a gas- 
liquid interface bioreactor to increase the time that the tissue slice could survive ex vivo 
[129]. The gas-liquid interface culture platform allowed Habeler and colleagues to 
functionally preserve the tissue slice for up to 80 days. Further application of this model 
demonstrated that 60 days after injection, ESC in the heart slice had adapted a cardiac 
myocyte like phenotype [130].
The future of more complex experimental treatments for heart failure will rely on 
better methods to understand these treatments. Models like surrogate heart tissue and 
heart slices have demonstrated their ability to make a significant impact on the 
development of novel treatments however, these models rely on complex substrates, and 
advanced bioreactors to simulate the necessary environmental signals. Further expansion 
of 3D tissue models to include cardiac fibroblasts will broaden our capacity to evaluate 
the next generation of treatments for chronic heart disease.
1.6 Summary, Overview, and Contributions 
There is an important opportunity for advanced cell culture platforms to make a 
significant impact on the standard treatment of heart failure by helping successfully
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design stem cell therapy treatments. In this chapter the physiologic role of the cardiac 
fibroblast, the impetus and mechanics of heart failure, cardiac cell therapy, and state-of- 
the-art cell culture and tissue engineering models were reviewed. The overarching 
objective of the research described in this dissertation was to directly correlate MSC 
treatment with CFb mediated changes in stiffness. This objective was addressed through 
the development of culture materials, a specialized bioreactor and utilization of newly 
developed methods to coculture fibroblasts and MSCs.
In Chapter 2 the design requirements and specifications for foundational 
equipment used in all further chapters are described. Chapter 2 includes a description of 
pertinent design spray parameters, as well as the mechanical design for the spray 
assembly and substrate fixturing.
In Chapter 3, novel methods for fabricating a porous polyurethane substrate that 
mimics the mechanical anisotropy of ventricular heart tissue are described. Dual spray 
nozzles were mounted onto a three axis computer numeric control robot (see appendix A 
for engineering drawings of spray platform). An elastomeric poly(ether-urethane) 
dissolved in N-dimethylacetamide (DMAc) was sprayed through one nozzle while a 
water-alcohol mixture serving as the nonsolvent was sprayed simultaneously through the 
other. The polymer begins to precipitate on the spray substrate as the solvent is diluted in 
the nonsolvent. After spray deposition, the biomaterial was uniaxially strained in custom 
frames that held the material in an elongated conformation during the curing period. After 
24 hrs the biomaterial had relaxed and cured sufficiently to be removed from the frames 
while permanently maintaining the elongated architecture. Electron microscopy, 
gravimetric porosity analysis, and mechanical testing were used to evaluate the
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architecture of the biomaterial. To validate that the architecture observed through 
characterization testing would influence cell behavior, 3T3 murine dermal fibroblasts 
were seeded and cultured on 250 ^m thick sheets. A two-dimensional fast fourier 
transform (2D FFT) was used to evaluate cell alignment with the direction of postspray 
elongation. Fibroblasts were observed to increase alignment of cytoskeletal actin 
filaments as the degree of postspray elongation increased. To demonstrate further 
flexibility of the substrate, multiple thin sheets were laminated after spraying. After the 
curing period, thick robust sheets were observed with little discernible evidence of 
lamination boundaries when imaged with an electron microscope.
In Chapter 4 two different methods for supporting cell populations in the interior 
of a 1 mm thick laminated substrate were developed and evaluated: (1) development of 
channel-like features running along the length of the substrate, and (2) development of 
perfusion seeding and culture. Phase separation molding techniques were adapted to the 
sprayed phase separation technique described in Chapter 3. Computer aided design 
(CAD) techniques and rapid stereo-lythographic prototyping were employed to fabricate 
corrugated spray substrates. Sprayed phase separation of the polymer onto this surface 
yielded reciprocal corrugations on one surface of the porous polyurethane material. 
Electron microscopy characterization confirmed that the corrugation pattern closely 
resembled the CAD pattern. Lamination of six corrugated sheets created a composite 
substrate approximately 1 mm thick with channel-like features arrayed in parallel along 
the length of the material. Hydraulic permeability testing confirmed the functional 
performance of the channels. One of the fundamental limitations of 3D materials for cell 
culture is inadequate mass transport near the cells. A perfusion bioreactor was design to
allow continuous perfusion through the channels and porous matrix of the substrate. 
Human mesenchymal stem cells were seeded either using a surface or perfusion 
approach. Following a 7 day culture period, cellularized samples were evaluated for cell 
density and cell distribution. Perfusion seeding and culture were observed to increase cell 
density and provide a more homogenous distribution of cells through the substrate. The 
presence of channel-like features in the substrate increased cell density in perfusion 
seeded samples when compared to nonchanneled materials.
In Chapter 5, the perfusion culture system was modified and utilized in 
conjunction with the channeled substrate to evaluate the effect of MSC coculture on CFb- 
mediated changes in stiffness. Appendix B contains engineering drawings and design 
considerations for the individual perfusion cassette cell culture platform used in Chapter
5. Chapter 5 first describes design and validation of the culture platform. Dermal 
fibroblasts were used to evaluate fibronectin preconditioning of the substrate and 
optimize seeding flow velocity for cell density and distribution. Cardiac fibroblasts were 
then used in a second seeding optimization investigation seeding velocity and duration. 
The purpose of the culture platform is to allow direct evaluation of treatment induced 
changes in stiffness. To validate that the model is capable of detecting increases in 
stiffness, dermal fibroblasts were cultured with and without ascorbic acid. Stiffness 
assessment demonstrated a significant increase between acellular substrates and 
fibroblast seeded constructs, and again between fibroblast seeded constructs without 
ascorbic acid supplementation, and constructs with ascorbic acid supplementation. To 
validate that the model was capable of detecting treatment induced decreases in stiffness, 
a common ACE inhibitor that has been shown to inhibit fibroblast mediated fibrosis was
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used to treat cardiac fibroblast seeded constructs. After cell culture, the stiffness of the 
ACE inhibitor treated group was significantly less stiff than untreated CFb group. To test 
whether MSC coculture influence stiffness, CFb and MSC were cultured together on the 
substrate. End-point stiffness assessment revealed that MSC coculture resulted in 
increased stiffness. Confocal imaging revealed that MSC were present and type III 
collagen was expressed in higher abundance in the coculture samples.
Chapter 6 discusses the conclusions from this work, specifically that MSC 
increase construct stiffness when cocultured with CFb. These findings seem to indicate 
that clinical application of MSC to alter is stiffness is a feasible approach to treating 
passive biomechanical heart pathologies. Moreover, future development of stem cell and 
pharmacologic therapeutics be evaluated using the model platform described in this work 
to quantitatively evaluate treatment induced changes in stiffness.
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CHAPTER 2
DESIGN OF SEMIAUTOMATED TOOLING 
FOR FABRICATION OF POROUS 
POLYURETHANE FOAMS
2.1 Introduction
Through all of the work described in this dissertation, substrates were fabricated 
using custom, semiautomated tooling. Development of this tooling was performed prior 
to the research described in Chapters 3-5. The fundamental purpose of this tooling was to 
enable production of biomaterials to be used as three-dimensional substrata for cell 
culture. Beyond this requirement, consideration was given to reproducibility of output 
materials independent of the operator, and a high degree of flexibility to adapt this 
process to the unique requirements of small batch production. A combination of custom, 
and off-the- shelf components were used to build the spray tooling. The primary 
components of the spray assembly are a computer, off-the-shelf syringe pump, CNC 
robot (Fig 2.1 MaxNC, Gilbert AZ), the nozzle assembly (Fig 2.2), and the spray surface 
assembly (Fig 2.3). The spray surface assembly is comprised of a spray plate (Fig 2.4) on 
top of a waste reservoir (Fig 2.5). A silicone substrate (Fig 2.6) was used in Chapter 4 for 
sprayed micromolding of the material. Polyester frames (Fig 2.7) were used in the spray
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surface assembly to facilitate handle-ability of the material after production. A mask (Fig
2.8) was aligned using alignment pins anchored to t-nuts on the surface of the CNC (Fig
2.9). At the end of this chapter, the engineering assembly drawings, part drawings, and 
bill of materials are included to describe the geometric and mechanical configuration of 
this device. Validation of the ability of this system to produce porous polyurethane 
substrates for use as cell scaffolding in cell culture is included in Chapter 3 and 4.
2.2 Spray Parameters 
The important inputs to the spray process include the volume of polymer solution 
on the deposited on surface, the rate of deposition, the spray pressure, the spray pattern, 
and curing conditions. These parameters and their influence on the overall process are 
described in detail in the following sections.
2.2.1 Polymer Deposition
The volume of polymer deposited on the spray surface is determined by the 
concentration of the polymer solution and the volume of this solution that is pumped 
during spray. The polymer deposition was normalized to the area of the surface, yielding 
a coverage parameter measured in g/in2. For this work, a coverage value of 0.65 g/in2 
was found to yield acceptable substrates. The coverage parameter can be altered in a 
custom Matlab program that will automatically calculate the corresponding pump 
settings. This value is limited on the upper side by accumulation of solvent that is trapped 
within the precipitated material, resulting in resolubilization of the deposited polymer,
and loss of control over the porous architecture, and on the lower limit by the handle- 
ability of the material after deposition.
2.2.2 Rate of Deposition
The rate of deposition is a function both of flow rate from the pump, and speed of 
the CNC while it moves through the spray pattern (discussed below). Precipitation of the 
polymer appears to happen relatively quickly with respect to the deposition rate, 
therefore, we used deposition rates that corresponded to the maximum linear travel speed 
of the CNC. The deposition rate is a user input parameter that can be altered for more 
sensitive processes requiring more time for precipitation or curing during fabrication.
2.2.3 Spray Pressure
Air pressure is required to aerosolize the polymer and nonsolvent solution. 
However, upon precipitation, the polyurethane materials fabricated in this work were 
very fragile and easily susceptible to plastic deformation. Artifacts in substrate geometry 
resulting from air flow induced deformation were minimized through minimizing the air 
pressure, and maximizing the working distance between the nozzles (see Fig 2.2) and the 
spray surface (Fig 2.3, see below for more details on spray pattern). A minimum of 10 
PSI was required for adequate dispersal of the polymer and nonsolvent. Depending on the 
viscosity and surface tension of the solutions used, this value may potentially be reduced 
even lower. Regardless of the solutions used, air pressure should be minimized to 
decrease deformation of the substrate geometry by air flow.
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2.2.4 Spray Pattern
The spray pattern is determined by the nozzle itself, and the working distance 
between the nozzle and the deposition surface. Initial spray experiments using dye loaded 
solutions sprayed onto absorbent paper demonstrated a linear increase (R2=0.9995) in 
spray diameter as a function of the working distance from 7.6 cm to 17.8 cm. The 
maximum working distance with the spray plate (Fig 2.5) and waste reservoir (Fig 2.4) 
loaded into the assembly was 14.0 cm. A working distance of 13 cm was selected and 
calculated to produce a spray diameter of 5.1 cm at the surface. Due to the side-by-side 
arrangement of the nonsolvent and solvent spray nozzles (see Fig 2.2), nonuniform 
border regions exist around the border of the sprayed material. These regions, depending 
on their location receive either excess polymer solution, or excess nonsolvent. To ensure 
consistent material properties in the final biomaterial, a mask (Fig 2.8) was designed and 
incorporated into the spray surface assembly to separate the consistent center regions 
from the nonhomogenous border regions. The travel distance in the X and Y axis of the 
CNC robot, in conjunction with the offset of the nozzles in the cross head and working 
distance provide a maximum consistent spray region of 13.3 cm x 8.9 cm.
Beyond the available space to create a uniform spray deposition, the spray pattern 
itself was controlled. The CNC traversed the spray in a serpentine pattern. The pitch of 
the each traverse is a user input parameter, limited on the low end by the ability of an off- 
the-shelf syringe pump to consistently deliver low volumes, and on the high end by the 
diameter of the spray pattern by the nozzle. For this research, a 17 mm step over was 
found to provide good coverage, while working within an optimal flow rate for the pump. 
In addition to the pitch, the number of passes is a variable user input. We used two coats
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to create substrates that were approximately 200 p,m thick in order to return the spray 
nozzles to the start position at the end of a run, although fewer or more coats seemed to 
work equally well.
2.2.5 Curing Conditions
After spray, the majority of the solvent and nonsolvent are collected in the waste 
reservoir. Removal of residual solvent is necessary for curing the material. Removal of 
solvent can be accomplished through evaporation or through diffusion when submerged 
in a solvent-miscible nosolvent. For all the polyurethane material used in this research, an 
aqueous nonsolvent was used. It was observed that relative humidity impacted the curing 
process when solvent was allowed to evaporate. To control for variations in relative 
humidity, samples were cured in water to remove residual solvent. Another important 
environmental parameter influencing the rate of solvent removal is ambient temperature. 
It was observed that low temperatures appeared to decrease the rate of solvent removal, 
resulting in slower kinetics of precipitation, and generally, higher porosity. All 
experiments were performed at room temperature, and relied on nonsolvent composition 
to influence the kinetics of precipitation, but future applications could utilize temperature 
as well as nonsolvent composition to influence material architecture using this system.
2.3 Tooling Applications 
In the research described in this dissertation, the material used with system was an 
elastomeric poly (ether-urethane), however, while this was the only material used in this
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research, the tooling described in this chapter has also been used to deposit drug loaded 
poly (lactic-glycolic acid) (PLGA) coatings, and fabricate composite polyurethane 
/collagen blends. Future adaption of the spray parameters described in this section can be 
used to fabricate a wide variety of porous biomaterial sheets using the tooling described 
here.
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A B S T R A C T
This p a p e r  re p o r ts  a  m e th o d  to  fab rica te  an iso tro p ic  scaffolds o f  tu n ab le  p o ro sity  an d  m ech an ica l 
p ro p e rtie s . Scaffolds w e re  fab rica ted  usin g  a c o m p u te r  c o n tro lled  sp ray ed  p h a se  s e p a ra tio n  tech n iq u e . 
Follow ing fab rica tion , th e  sh e e ts  w e re  e lo n g a te d  0, 35 o r  70% o f  th e ir  o rig inal len g th  to  in d u ce  vary ing  
d e g re e s  o f  scaffold a lig n m en t an d  an iso tro p y . T he n o n so lv e n t u sed  in th e  p h a se  se p a ra tio n  w as sh o w n  
to  a ffect p o ro sity  a n d  th e  e la s tic  m o d u lu s . M o u se  em b ry o  NIH-3T3 fib ro b lasts  w e re  c u ltu red  o n  the  
scaffolds to  in v estig a te  cell re sp o n se  to  th e  a n iso tro p y  o f  th e  scaffold. A 2D FFT m e th o d  w a s  u sed  to  
q u a n tify  ce llu la r a lig n m en t. Cells w e re  sh o w n  to  align  th em se lv e s  w ith  th e  scaffold. This sh e e t- lik e  
scaffold m ate ria l c a n  be  u se d  in  single  plys o r  can  be  lam in a te d  to  fo rm  p o ro u s  3D co m p o s ite  scaffolds.
P u b lish ed  by E lsevier Ltd.
1. Introduction
Tissue engineering  and regenerative m edicine have the po ten­
tial to develop novel biosynthetic m aterials for im proved trea t­
m ent, m aintenance, and regeneration  o f d iseased o r dam aged 
tissue. D evelopm ent o f m aterials th a t utilize tissue engineering 
strategies requires design considerations such as cell type, seeding 
and attachm ent, as well as m olecular signals, and m acrom olecular 
m atrix in o rder to develop constructs th a t im prove or replace 
function of natural tissue [1-3]. M any types of engineered tissue 
rely on a provisional or perm anen t scaffold to generate  a th ree ­
dim ensional fram ew ork for cell a ttach m en t and tissue organiza­
tion. Both natu ral and synthetic scaffold m aterials are used in tissue 
engineering  [4,5]. Synthetically derived cell scaffolds can be 
perm anen t o r degradable and facilitate expression and organiza­
tion o f the extracellular m atrix  (ECM). A rchitectural cues in these 
scaffolds have been show n to affect the  morphology, organization, 
and phenotypic expression o f cells in vitro [6-8]. In o rder to 
develop effective im plants, the  tissue eng ineer needs to be able to 
specify and tune  the  scaffold’s m orphological features for different 
applications. In addition, scaffold architecture  m ust be designed 
to provide cues for cellular organization and form  th e  basis for 
engineered tissue constructs that m im ic tissue specific organiza­
tion and physical properties.
: Corresponding author.
E-mail address: r.hitchcock@utah.edu (R.W. Hitchcock).
Cardiac tissue is an exam ple o f highly structu red  tissue th a t 
relies on cellular organization  for its function [9,10]. Cell scaffold 
m aterials can help cardiac tissue developm ent by: (1) providing 
cues th a t induce alignm ent of cardiac myocytes, (2) allowing 
sufficient n u trien t and cell infiltration necessary to form a 3D tissue 
construct, (3) m odulating  the  cell type d istribution  o f co-cultures, 
and (4) m im icking anisotropic m echanical stiffness o f the heart. 
Scaffolds used for cardiac tissue engineering applications require 
developm ent o f design specifications th a t include scaffold align­
m ent, structure , porosity, and stiffness all of w hich will influence 
cellular developm ent, overall tissue organization, and bioreactor 
integration [11-13].
Various m ethods have been  em ployed to fabricate scaffolds o f 
varying porosity and anisotropy. For exam ple, m icrofabrication 
techniques have been used to fabricate scaffolds w ith  aligned 
s truc tu re  [14,15]. Electrospinning m ethods have been em ployed 
w ith  post process elongation to produce anisotropic fibrous scaf­
fold architecture [16]. In order to create  scaffolds th a t allow 
adequate  nu trien t and oxygen diffusion, m ethods such as 3D fiber 
deposition, sacrificial fiber electrospinning, and phase separation 
have been utilized to generate  scaffolds of controlled porosity 
[17-20]. Spray phase  separation  (SPS) is m ethod for creating scaf­
folds w ith  control over alignm ent, porosity, and stiffness; how ever 
this m ethod has not been directly applied for cardiac tissue scaf­
folds [19].
SPS fabricated scaffolds are produced using a m ethod that 
sim ultaneously  sprays a polym er so lution and a nonsolvent onto 
the  surface. The nonsolvent mixes w ith  the  solvent and the
0142-9612/$ -  see front m atter Published by Elsevier Ltd. 
doi: 10.1016/j .biomaterial s.2009.10.024
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polym er causing the  polym er to precipitate. Some groups have 
used SPS m ethods to fabricate m aterials o f varying porosity for 
drug delivery devices [21 ] and vascular graft m aterials [19,22]. SPS 
fabrication is a prom ising m ethod for controlling scaffolds p rop­
erties such as alignm ent, porosity, stiffness, and anisotropy, w hich 
are key features for directing  cellular developm ent, overall tissue 
organization, and bioreactor integration  [11-13].
W e hypothesized th a t post spray elongation o f  SPS scaffolds 
w ould generate  scaffold m icrostructure  a lignm ent and in tu rn  
induce cellular a lignm ent. Furtherm ore, w e hypothesized th a t the 
nonsolvent (NS) EtOH concentration  would affect scaffold porosity. 
In addition, w e hypothesize tha t this m aterial m ay be lam inated 
into thick scaffold m aterial. Here w e report an SPS m ethod for 
fabricating polyurethane scaffolds for tissue engineering 
applications.
2. M aterials and m ethods
2.1. Scaffold fabrication
Scaffolds w ere fabricated using an SPS m ethod. A 4% polyurethane solution was 
prepared by dissolving Tecoflex SG80 polyether polyurethane (Lubrizol Advanced 
Materials Inc. Cleveland, OH) in dimethylacetamide (DMAc) (Sigma Aldrich, St. 
Louis, MO). Polyether polyurethane was selected because of its known biocompat­
ibility, ease of processing, and extensive use in the  past for scaffold materials 
[23-25]. The polymer solution was sealed in glass storage containers prior to use and 
used immediately after opening to  ensure that minimal solvent was lost through 
evaporation. Deionized w ater (referred to as 0% ethanol), 50% EtOH, and 70% EtOH 
solutions were used as the nonsolvent for precipitation.
Spray nozzles (Excel ES4, Porter Cable, Jackson, TN) were m ounted onto 
a custom  crossbar attached to the spindle head of a computer-controlled desktop 
milling machine (MaxNC 12, MAXNC, Gilbert AZ) to  provide X-Y-Z control o f spray 
pattern. Custom G-code was used to move the spray head and control the spray 
pattern and spray time. The spray nozzles traversed the substrate at a distance of 
20 cm and a speed of 0.85 cm/s in a serpentine pattern yielding a total spray time of 
2.5 min.
Aluminum frames w ere designed to facilitate m anipulation and mechanical 
alignm ent of the  scaffold m aterial during and after spraying. The fram es were 
fabricated from 0.32 cm thick 6016-T6 alum inum  (McMAster-Carr, Princeton NJ) 
with an outside dimension of 5.3 cm x 3.7 cm and an inside dimension of 
2.86 cm x 2.54 cm. Stainless steel hypoderm ic tubing sliders (Small Parts Inc., 
Miramar, FL) w ere assem bled and attached to frames w ith UV cure adhesive to 
facilitate elongation and constrain the maxim um  elongation to 3.86 cm (35% 
elongation) or 4.86 cm  (70% elongation). Frames w ithout sliders were used to 
m ake scaffolds with no in-process m echanical alignm ent. Stainless steel screens 
(Type 316 Mesh #60, Small Parts Inc.) w ere attached to the opposite ends of the 
frame to provide a rigid, yet porous surface for scaffold adherence. A sheet of 
0.32 cm thick alum inum  (McMaster-Carr) was coated w ith silicone (VST 50 silicone 
elastomer. Factor II Inc., Lakeside, AZ) to prevent the scaffold from sticking to the 
aluminum. Three fram es (one of 0%, 35% and 70% elongation) w ere clam ped to this 
silicone coated alum inum  backing which was subsequently placed inside the spray 
chamber.
The polymer solution and nonsolvent were sprayed simultaneously onto the 
frames at a pressure of 40 psi. Spray rates were calculated by m easuring the mass 
loss of the spray reservoir after a 30 s test spray. Spray rates o f the polymer solution 
and the  nonsolvent w ere adjusted on the  spray nozzle to 7.5 ±  0.5 g/min and
45.0 ±  5.0 g/min respectively to achieve uniform scaffold structure.
After the spray process was completed, scaffolds w ere immediately rinsed with 
gently flowing DI w ater for 1 min. The frames were then removed from the 
aluminum backing, and scaffolds w ere elongated 0%, 35% or 70% of their original 
length and allowed to dry for 24 h in the  stretched conformation. After the scaffolds 
were dry, they were removed from the frames for testing.
22. Mechanical testing
Mechanical properties were m easured in the  direction aligned with the in­
process elongation (preferred direction) and perpendicular (transverse) to this 
direction. A sample was removed from the center of each scaffold for mechanical 
testing (n =  3). The samples used for longitudinal testing measured
20.0 m m  x 5.0 mm and the samples used for transverse testing measured
5.0 m m x  1.5 mm. These sizes were chosen based on the physical limitations of the 
scaffold and frame configuration. Samples w ere tested on  an Instron 3342 (Instron, 
Norwood MA) with a 50 N load cell. A gauge length of 10 mm was used for longi­
tudinal testing, while a gauge length of 3 mm was used for transverse testing. The 
samples w ere tested to 40% strain at a speed of 20 m m/min. The effective stress for
each sample was calculated by dividing the force by the overall cross section. From 
the  effective stress and strain data an effective modulus of elasticity was calculated 
in both the  preferred and the  transverse direction. Anisotropy is reported as the ratio 
of the  effective m odulus in the preferred direction to the effective m odulus in the 
transverse direction.
2.3. Porosity
Porosity is defined as the ratio o f the void space to the total volume of a solid. 
Total volume was calculated by m easuring length, w idth and height of rectangular 
scaffold samples [26]. The mass o f the scaffold samples was then used in conjunction 
w ith the specific gravity of Tecoflex SG80 polyurethane (1.04 g/cc) to determine the 
volume of polyurethane in the sample. Void space was the difference in volume 
between the total volume, and the volume of the polyurethane. Porosity was 
calculated as the ratio of void space to total volume of the scaffold.
2.4. Cell culture and seeding
Mouse embryo fibroblast NIH-3T3 cells were cultured in Dulbecco's modified 
Eagle medium (DMEM) with 10% FBS and 1% L-glutamine, and 1% penicillin and 
streptomycin (Invitrogen, Carlsbad, CA). All culture media mentioned herein is the 
same as described above unless otherwise noted. Cells w ere cultured in a T- flask 
(Fisher Scientific, Waltham, MA) and media was changed twice per week until they 
reached approximately 90% confluence. Cells were then passaged. Briefly, culture 
media was removed from the cells. Cells were then rinsed with sterile PBS to remove 
any remaining culture media. Trypsin was added to the flask, and allowed to act for 
2 -4  min. a t  37° C. Fresh media was then added to quench the  trypsin. Cells were 
centrifuged and the supernatant discarded. The cell containing pellet was then 
resuspended in fresh media and transferred to a new T-flask. Cells were passaged 
three times before seeding onto the scaffold.
Prior to seeding, scaffolds were sterilized by spraying with 70% EtOH and rinsing 
w ith sterile PBS and culture media. Cells were removed from the surface o f the cell 
culture flask via trypsinization as described above. These cells w ere then separated 
from trypsin through centrifugation and resuspended in cell culture media. 
Approximately 3.5 x 107 cells were seeded by gently pipetting 500 nl of the cell 
suspension onto the surface of the scaffold in a 100 m m  plastic culture dish (Fisher 
Scientific). Cells were allowed to attach for two hours according to previously 
published methods (7) before the scaffold was covered with fresh culture media. 
Media was replaced w ith fresh media twice each week for 14 days.
2.5. Cell imaging and analysis
Following cell culture, cells w ere imaged w ith fluorescein diacetate (FDA) 
(Invitrogen) to ensure that viable cells w ere p rese n t The cells w ere then  fixed with 
4% paraformaldehyde, and stained with DAP1 (Invitrogen) for nuclei visualization 
and phalloidin conjugated with alexafluor 488 (Invitrogen) for actin filament 
visualization according to the  m anufacture’s guidelines. Images w ere then 
collected using an Olympus FV 1000 (Center Valley, PA) confocal microscope 
starting a t the surface of the scaffolds, and capturing image slices every 5 nm to 
a depth o f 50 urn. These stacks were then  projected into a single image of the 
maxim um  intensity pixels through scaffold using ImageJ, (NIH imaging software. 
Bethesda MD).
Image analysis was performed on the projected images using custom written 
MATLAB code. A 2D FFT m ethod similar to w hat is reported by Ayers e t al. was used 
to  m easure the direction fiber alignm ent [27]. Briefly, randomly selected regions of 
cell growth were processed with a Gaussian filter in order to reduce edge effects. A 
2D FFT was performed and filtered to include only frequencies from 20-50  pixels. 
This range was selected based on the average spacing of actin filaments in the 
images in order to decrease artifacts from larger structures such as scaffold struc­
ture. Average pixel intensity was m easured a t every angle in the frequency range 
mentioned above. Average pixel intensity was plotted w ith respect to the angle from 
horizontal, and shifted 90° to align the peak w ith the direction o f actin filament 
alignment. Cellular alignment is reported as the orientation index, which is defined 
as the angle that captures 50% of the  actin filament alignment, as determ ined by the 
area under the average pixel intensity curve.
2.6. Scaffold lamination
In order to generate thicker materials, scaffolds were laminated during the 
drying process. Scaffolds were fabricated as described previously and elongated 70%. 
Instead of drying overnight individually, five scaffolds were placed one on top of 
another and allowed to dry. During the drying process the  scaffolds formed 
a continuously adhered lamination. After the laminated scaffolds had dried, they 
w ere frozen in liquid nitrogen and broken to expose the  cross section. The cross 
section of these thick scaffolds was observed through electron microscopy to 
qualitatively assess pore structure and the  lamination interface.
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Post Spray Elongation (%)
Fig. 2. Effective modulus of elasticity of scaffolds fabricated with (A) 0% EtOH, (B) 50% EtOH, and (C) 70% EtOH. Longitudinal moduli were compared to 0% elongation (*). 35% and 
70% scaffolds were compared to themselves in the longitudinal and transverse directions (f).
to im age individual actin  filaments. Scaffolds w ere  im aged a t 5 ^im 
intervals from the  surface o f the  scaffold to a dep th  of 50 |im. Cells 
w ere  generally observed to be aligned w ith  scaffold filam ents and 
along the  pore edges o f the  m aterial. An exam ple o f a typical 2D FFT 
and pixel intensity  plot a re  show n in Fig. 5A and B respectively. 
O rientation  index decreased  as post-spray  elongation increased 
(p <  0.05)(Fig. 6). Lower o rien tation  indices rep resen t m ore aligned 
actin  filam ent orientation . No significant differences w ere  observed 
betw een  50% EtOH NS and 70% EtOH NS scaffolds of equal 
elongation.
3.4. Scaffold lamination
Five scaffolds w ere  lam inated  together to create a m aterial w ith 
an  increased thickness. The overall thickness w as 825 ±  102.1 ^m. A 
cross sectional view  o f the  scaffold reveals a highly porous structure  
(Fig. 7). The lam ination  boundaries are undetectable.
4. Discussion
Aligned scaffolds have been show n to facilitate organization  of 
cells in engineered cardiac tissue constructs [6]. Properties such as 
anisotropy and porosity have been show n to influence cell d is tri­
bution  and  cellular a lignm ent w ith in  scaffolds [28,29]. We have 
developed a m ethod for fabricating sheet-like po lyurethane scaf­
folds o f tunable porosity and anisotropy. W e hypothesized tha t post 
spray elongation o f spray  phase separation  (SPS) scaffolds would 
generate  scaffold anisotropy th a t would induce cellular alignm ent.
0% EtOH NS (porosity  o f 70 ±6% ) w as low er than  those fabricated 
w ith  50% EtOH NS (porosity of 78 ±3%, p =  0.0006) (Fig. 3). Scaf­
folds fabricated w ith  70% EtOH (porosity  of 88 ±  2%) had a signifi­
cantly higher porosity than  scaffolds fabricated w ith  50% EtOH NS 
(p =  0.00014).
3.3. Cellular alignment
To de term ine  the  effect o f the  scaffold m icroarchitecture on 
cellular alignm ent, actin filam ents of the  cells w ere  stained w ith  
phalloidin and nuclei w ere stained  w ith  DAPI (Fig. 4). Cells w ere 
im aged a t 20x m agnification in o rd e r to include the  largest num ber 
of cells in th e  field o f view  w hile m aintain ing  sufficient resolution
Table 1
Effective m odulus of elasticity in the preferred and transverse directions and 











0% 0% 1.18 ±0.02 NA NA
35% 1.43 ±0.07 1.18 ±0 .05 1.21
70% 1.53 ±0.05 0.83 ±  0.05 1.85
50% 0% 0.32 ±  0.02 NA NA
35% 0.46 ±  0.04 0.44 ±0 .033 1.04
70% 0.57 ±  0.03 0.27 ±0 .07 2.12
70% 0% 0.18 ±0.03 NA NA
35% 0.27 ±  0.05 0.22 ±0 .04 1.23
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A B S T R A C T
S caffo ld -based  tissu e  e n g in e e rin g  p rov ides cells w ith  an  en g in e e red  m atr ix  to  e n h a n c e  an d  d ire c t cell 
a tta c h m e n t,  p ro life ra tio n  an d  d iffe ren tia tio n . O ne c ritica l l im ita tio n  to  c u rre n t t issu e  e n g in e e rin g  
ap p ro ach es  is th e  in ab ility  to  c re a te  d e n se ly  p o p u la te d  co n s tru c ts  th ic k e r  th an  a few  100 pm . W e h y p o th ­
esized  th a t d e v e lo p m en t o f  po rous, ch an n e le d  scaffo lds w o u ld  in crease  cell d e n s ity  a n d  u n ifo rm ity  of 
th e ir  sp a tia l d is tr ib u tio n  th ro u g h  scaffold c h an n el perfu sio n . P a tte rn ed  p o ly u re th an e  sh e e ts  w e re  fab ri­
c a te d  usin g  a sp ray ed  p h a se  sep ara tio n  tec h n iq u e  and  lam in a ted  to g e th e r  to  fo rm  1.5 m m  th ick  c h a n ­
n e led  scaffolds. H ydrau lic  p e rm e a b ility  te s tin g  co n firm ed  th e  p re se n c e  o f  fu nctional chan n els  
th ro u g h o u t th e  m u ltila m in a te  co n s tru c t. A c o n tin u o u s  flow b io re a c to r w as u sed  to  p e rfu se  th e  co n s tru c t 
w ith  m ed iu m  d u rin g  th e  c u ltu re  period . C ross-sectional cell d e n s itie s  an d  sp a tia l u n ifo rm itie s  w e re  m ea­
su re d  in ch an n eled  and  n o n ch an n eled  scaffolds u n d e r  d iffe ren t seed ing  and  cu ltu re  co nd itions. Chan­
n e led  scaffo lds w e re  found to  h ave  h ig h er d e n s itie s  o f  h u m an  m esen ch y m al s te m  cells  th an  
n o n ch an n eled  sam ples. P erfused  scaffolds had  m o re  u n ifo rm  sp a tia l d is tr ib u tio n  o f  cells  w ith in  th e  scaf­
fold c o m p ared  to  s ta tica lly  c u ltu red  scaffolds. In conc lu sio n , w e  h av e  sh o w n  th e  ch an n e le d  scaffolds to  be 
a p ro m isin g  a p p ro ach  to w a rd  c rea tin g  th ick  tis su e -e n g in ee re d  co n stru c ts .
© 2011 Acta M ateria lia  Inc. P ub lished  by E lsevier Ltd. All r ig h ts  reserved .
1. Introduction
The design and preparation  of functional tissue is a prim ary goal 
of tissue engineering (TE). Once prepared, in vitro engineered tissue 
can be used for trea tm en t of diseased or dam aged tissue, pharm a­
cological screening, or research on m olecular m echanism s and 
developm ental biology [1-3]. TE harnesses the regenerative capac­
ity o f cells to  assem ble functional tissue and utilizes the  engineer­
ing paradigm  to design and create appropria te  environm ents for 
developing engineered tissue. Cells require stim uli such as soluble 
chem ical signals (e.g. oxygen, cytokines, nutrien ts), cell-cell/ce ll- 
extracellular m atrix  (ECM) adhesion [4,5], m echanical forces (e.g. 
shear stress, strain) [6,7], surface interactions (e.g. texture, archi­
tecture, surface energy) [8,9] and electrical s tim ulation [10,11] to 
develop in to  functional tissue. In tissue culture environm ents, sol­
uble chem ical signals are found in culture m edia, bioreactors can 
provide m echanical and electrical stim ulation, and scaffolds pro­
vide a provisional m atrix  that can be supplem ented  o r replaced 
by cell expressed ECM over time. Currently, one m ajor challenge 
facing tissue engineers is the  lim itation of relying on diffusion to 
deliver soluble chem ical factors. W ithou t enhanced transport, m et- 
abolically active cells deeper than  about 100 pm  do not receive 
sufficient soluble chem ical signals, nu trien ts  and oxygen [12]. They 
are  unable to survive beyond the  diffusive lim its of a nu trien t
* Corresponding author. Tel.: +1 801 557 7393.
E-mail address: r.hitchcock@utah.edu (R.W. Hitchcock).
source, and therefore  are unable to assem ble functional tissue
[13]. For tissue such as cardiac m uscle, contractile force is directly 
correlated to the  thickness and cellular density  of the construct
[14], The lim itation of construct size has h indered developm ent 
and clinical application of tissue-engineered constructs.
To overcom e diffusion related lim itations, there  a re  tw o general 
approaches. One approach aim s to increase the  effective diffusive 
length, w hich will allow cells deeper w ith in  a construct to ex­
change sufficient nu trien ts  and w aste  for survival. The effective 
diffusion d istance can be increased th rough the  use  of hydrogels
[15] and increased porosity [16], and w ith  the  use o f specialized 
carriers, such as perfluorocarbons, to increase the concentration 
o f oxygen in the  m edium  [17],
Another approach to overcom ing diffusional lim itations utilizes 
convective transpo rt (perfusion) to  bring nu trien t-rich  m edium  
nearer to the  cells, thus decreasing the  need for long-range diffu­
sion. Perfusion can occur e ither in vivo, th rough  the  host’s cardio­
vascular system , or in vitro, through a perfusion bioreactor. In the 
in vivo case, pre-vascularized constructs have been em ployed to 
facilitate vascular perfusion [1,18,19], Prevascularization utilizes 
a com bination o f cells, structu res and signals to facilitate and 
accelerate functional anastam osis upon im plantation  [20,21 ]. In vi­
tro  perfusion has been accom plished by pum ping m edium  e ither 
transm uraly, through porous scaffolds, o r through channel net­
works [22-26]. Further developm ent of perfusion-based TE tech­
nologies m ay provide a so lution to the challenges associated 
w ith  construct size.
1742-7061/$ - see front m atter © 2011 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. 
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One advantage of the  perfusion approach is the high degree of 
control th a t can be designed in to  the  system . The prim ary variables 
that affect m ass transport are the  perfusion ra te  and the scaffold 
configuration. Scaffold perfusion m odels predict th a t oxygen gradi­
ents can be a ltered through judicious design o f scaffold properties 
and perfusion ra tes  [27-29]. One scaffold property tha t has been 
studied in these m odels is a netw ork of engineered channels w ith ­
in the scaffold. Channels for perfusion have been proposed to pro­
vide an in vivo-like oxygen supply to cells [301. Convective 
transport through a channel array can bring nu trien ts and oxygen 
near enough to cells to allow sufficient d iffusion-based exchange to 
prom ote cell viability. This approach is inherently  biom im etic as it 
uses a vasculature-like array to provide local exchange of m etabo­
lites and w aste  products to and from cells w ith in  a thick tissue 
[22,23]. M oreover, channels can be used to endow  a scaffold w ith 
geom etric and m echanical cues th a t direct cellular alignm ent 
[25]. In addition, channels m ay help shield cells from shear stresses 
associated w ith  perfusion, w hich have been show n to be de trim en­
tal to som e cell types [17,31 ]. Overall, engineered channels for per­
fusion are a prom ising platform  for overcom ing diffusion related 
problem s in tissue engineering.
Scaffolds, in addition to their role in helping m eet m etabolic 
requirem ents, m ust m eet certain  perform ance and com patibility 
requirem ents, such as porosity, stiffness and anisotropy. Scaffolds 
th a t can be engineered to m eet these  requirem ents are key to 
developing platform s for creating functional engineered tissue. 
The ability to create a scaffold th a t not only facilitates sufficient 
transport of m etabolites, but also allows the engineer to control 
key design requirem ents will likely be a necessary tool for success­
ful scaffold-based technologies. D evelopm ent o f an engineered 
construct th a t is clinically useful will depend on successful engi­
neering designs th a t m eet all of these  requirem ents and likely 
more.
Our group has recently developed th in  shee t scaffolds m ade 
from polyether u rethane (PU) and show n th a t they can be engi­
neered w ith specific porosity, stiffness and anisotropy [32]. In 
addition, these  m aterials induce cellular alignm ent via scaffold 
m icroarchitecture and can be lam inated to form thick structures. 
In this paper w e investigate a channel-based m ethod to enhance 
transport and seeding efficiency w ith in  thick cell-laden constructs. 
Our goal is to develop a channeled scaffold for use w ith  perfusion 
culture. It has been show n that perfusion seeding and culture of 
thick constructs will enhance the density  and uniform ity o f tis­
sue-engineered constructs [24,27,30]. W e hypothesize that engi­
neered channels w ith in  the  scaffolds will further increase the cell 
density  of perfused constructs. Here, we report m ethods to design 
and fabricate channels in lam inate PU scaffolds, and in vitro testing 
of these channels to  evaluate cell density  and uniform ity.
2. Methods
2 .1. Scaffold fabrication
Scaffolds w ere fabricated using a sprayed phase separation 
technique. W e have previously show n tha t PU fabricated through 
sprayed phase separation can provide a porous struc tu re  that facil­
itates cell a ttachm en t and proliferation [32]. For this study, we 
used 4% (w /v) PU dissolved in d im ethylacetam ide. To create porous 
sheets, 70% ethanol (EtOH) was selected as the  nonsolvent [33]. 
This solvent w as sprayed a t a rate of 7.0 g  m in-1 ± 10%, w hile 
the nonsolvent w as sprayed sim ultaneously a t a ra te  of 
14.0 g m in-1 ± 10% onto  a patterned silicone substrate. Spray noz­
zles w ere m ounted onto an xyz control robot (MaxNC 12, Gilbert, 
AZ), and the  spray p a tte rn  and tim e w as controlled using a cus­
tom -w ritten  code.
Polyester fram es w ere  designed in order to enhance handleabil- 
ity  o f the scaffolds. Thin polyester film (0.25 mm  thick) was cut 
into a 9 x  6 m atrix  of fram es using custom  code and a knife p lo tter 
(Graphtec, Santa Ana, CA). Each fram e consists of a 13 x  20 mm  
w indow  w here the scaffold is deposited, tw o tabs for scaffold 
adherence and alignm ent holes for facilitating lam ination 
(Fig. 1 A). Im m ediately a fter spraying, the fram es (w ith  the scaffold 
attached) w ere rem oved from the substrate. Scaffolds w ere lam i­
nated using the alignm ent holes in the  frame (Fig. IB) and custom  
lam ination tooling. After lam ination, scaffolds w ere  allowed to 
cure overnight in a bath of deionized w a ter a t room tem perature  
to insure constant hum idity  during solvent removal.
In order to create  perfusion channels w ith in  the  scaffolds, the 
PU solution w as sprayed onto a silicone substra te  w ith the desired 
channel configuration patterned onto its surface. The channel con­
figuration w as designed using three-d im ensional (3-D) design soft­
w are (SolidW orks, Concord, MA). A mold for this configuration was 
then  fabricated using a 3-D p rin ter (Objet, Billerica, MA). Low vis­
cosity, tw o-part Pt cure silicone (VST-50, Factor II, Lakeside, AZ) 
was poured in to  the mold and allow ed to cure a t 40 °C overnight. 
The silicone was then  rem oved from the  mold and used as the  pa t­
terned  spray substrate.
Two different channeled and one nonchanneled configurations 
w ere fabricated. Both channel configurations had a nom inal depth  
and pitch of 350 and 875 f.im respectively. The larger channel con­
figuration had channels w ith  a nom inal w idth  of 500 \im , w hile the 
sm aller had a nom inal channel w idth  of 200 j.im (Fig. 2). These 
w idths w ere chosen based on  the capability of the  3-D prin ter 
and to provide a range o f channel w id ths com parable to o ther re­
ported channeled  scaffolds [24,25].
2.2. Scaffold characterization
M echanical properties w ere m easured for both channeled and 
nonchanneled scaffolds. A sam ple w as rem oved from the center 
of each scaffold for m echanical testing (n = 4). The te st specim ens 
m easured 16.0 x  5.0 mm. They w ere tested on an  Instron 3342 (In- 
stron, Norwood MA) w ith  a 50 N load cell. 2 m m  was gripped in 
each grip, resulting in a gauge length of 12 mm. The sam ples w ere 
tested to 40% strain a t a speed o f 20 mm  m in-1. The effective stress 
for each sam ple was calculated by dividing the force by the  overall 
initial cross-sectional area over the  linear range o f the  stre ss-s tra in  
curve (from  10% to 40%). From the effective stress and strain  data 
an effective m odulus of elasticity w as calculated.
Porosity w as determ ined by gravim etric and dim ensional anal­
ysis for both channeled and nonchanneled scaffolds (n = 4), as de ­
scribed previously [32,33]. Briefly, the total volum e (Vtotai) of the 
scaffold was calculated by m easuring the  dim ensions (/, w, h ) of 
rectangular scaffold sam ples (approxim ately 1 5 x 5 x 1  m m ). The 
m ass o f the scaffold sam ples (mscaffoid) was then  used in conjunc­
tion w ith  the specific gravity (p PU) of Tecoflex SG80 PU 
(1.04 g cc-1 ) to determ ine the volum e of PU in the  sam ple. The void 
volum e is the difference betw een the total volum e and the  volum e 
occupied by PU in the  scaffold. The porosity w as calculated by
Fig. 1. (A) Polyester frame used to enhance handleability of scaffold. (B) Schematic 
of lamination procedure. Six scaffolds (approximately 0.25 m m thick each) were 
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Modified t-flask
Peristaltic pump
Fig. 4. (A) The culture chamber included six barbed connectors for m ounting scaffolds. A window was cut in the top of the  t-flask for loading scaffolds, and a film with a 
weakly adhesive border was used to close the window in order to maintain sterility. A drain was installed on the opposite side of the flask. (B) Schematic of the perfusion 
bioreactor. Medium was pumped from a reservoir using a peristaltic pump to the culture chamber. Drainage from the culture chamber was recycled back to the reservoir.
have been show n to be acceptable for cells sensitive to shear stress 
(cardiom yocytes) [17],
2.6. Cell seeding and culture
H um an m esenchym al s tem  cells (hMSCs) w ere grow n in a 
T-flask p rio r to  seeding. Cell cu lture m edium  w as com posed o f 
Dulbecco’s modified Eagle’s m edium  (DMEM; Fisher Scientific, 
W altham , MA) supplem ented  w ith  10% fetal bovine serum  (FBS), 
2 nM L-glutamine and 50 |il m l-1 streptom ycin  50 U m l-1 penicil­
lin (Invitrogen, Carlsbad, CA) [36], Prior to seeding, scaffolds w ere 
sterilized w ith  ETO. Scaffolds w ere  im m ersed in 70% EtOH in order 
to w et all th e  pores. Scaffolds w ere  then  rinsed three  tim es w ith  
sterile PBS to rem ove the  EtOH. Following w etting  and rinsing, 
scaffolds w ere im m ersed in culture m edium  for 24 h in  order to  
condition the  scaffold w ith  FBS proteins. After conditioning, the 
m edium  w as rem oved and th e  cells w ere seeded onto  the  scaffolds 
using one of tw o m ethods. Surface-seeded scaffolds w ere seeded 
by placing 500 pi o f 1.85 x 106 ± 0.43 x 106 cells m l-1 cell suspen­
sion on  th e  surface. Perfusion-seeded scaffolds w ere  seeded by 
flow ing5 0 0 p io f  1.85 x  10s ± 0 .43  x  106 c e l l s m r 1 cell suspension 
through th e  scaffold using  a syringe coupled to the  silicone connec­
to r over 1 m in. Experim ental groups o f channeled (500 pm  only) 
and nonchanneled scaffolds (n  = 3 o f each type) w ere tested  for s ta ­
tic cu ltu re  surface seeding, static  cu lture perfusion seeding, perfu­
sion culture  surface seeding and perfusion culture perfusion 
seeding. After a 1 h a ttachm en t period, all scaffolds w ere  sub­
m erged in fresh m edium . Static cu ltu re  specim ens w ere cultured 
individually in cell cu lture  dishes w ith  a m edium  volum e o f 9 ml. 
The m edium  w as exchanged five tim es for th e  static  cu lture sam ­
ples. Two hours a fter seeding, perfusion o f the  dynam ic cu ltu re  
w as com m enced a t a ra te  o f 3 ml m in-1 . Perfusion cultured  sam ­
ples used 250 ml o f m edium  th a t w as recycled through  the  biore­
actor. The to ta l volum e o f m edium  used per scaffold in bo th  cu ltu re  
conditions (static  and perfused) w as 45 ± 3 ml. Cells w ere cultured 
for a total o f 7 days.
2.7. Cell distribution analysis
After the 7 day culture period cells w ere fixed overnight a t 4  °C 
w ith  4% paraform aldehyde. The scaffolds w ere  then  equilibrated in 
a 30% sucrose so lution (Fisher Scientific) overnight. After equilibra­
tion, scaffolds w ere  covered w ith  tissue-freezing m edium  (Triangle 
Biomedical Sciences Inc., Durham, NC) overnight. Thin cross-sec­
tions (100 pm ) o f the  scaffold w ere obtained using a Leica 1950 
CM cryostat (Leica M icrosystem s, W etzlar, Germany). Nuclei of 
cells in the  th in  sections w ere then  fluorescently stained w ith  
4 '.6-d iam idino-2-phenylindole (DAP1). Cells w ere imaged w ith  an 
O lympus FV 1000 confocal microscope (Olympus, Center Valley,
PA). C ustom -w ritten  M atlab code w as used to  quan tita te  the num ­
ber o f cells in e ight equally spaced regions o f the  scaffold from  one 
surface to th e  opposite surface. M anual cell nuclei counts w ere ob­
tained and com pared to o u tp u t from the  M atlab code in order to 
validate th e  program . A utom ated cell counts w ere w ith in  2% o f 
m anual cell counts. Both cell num ber and uniform ity a re  pre­
sented. The percentage o f cells (n,) in each segm ent w as used to 
calculate the  uniform ity index (UI), as show n in Eq. (3). For this, 
12.5% (the  value representing  a perfectly uniform  distribution  for 
eight segm ents) w as sub tracted  from  th e  percentage of cells in 
each segm ent. The data  w as norm alized by dividing it by 175, 
the m axim um  value for a non-uniform  distribution:
Ul — i  _  Z)i-i lni ~ 12.5|
2.8. Statistics
(3)
A single-factor analysis of variance (a  -  0.05) w as used to com ­
pare cell uniform ity  and  cell density  values for the  different seed­
ing and culture conditions. Unpaired t-tes ts  w ere used to  assess the  
significance of the  m echanical properties, porosity, cell uniform ity, 
density  and hydraulic perm eability  o f scaffolds.
3. Results
3.1. Scaffold dimensions and mechanical testing
Six individual polyurethane sheets w ere lam inated to create 
each scaffold. These lam inated scaffolds w ere 1.17 ± 0.13  m m  
thick. M echanical testing  show ed no difference betw een the  m od­
ulus o f 500 pm  channeled  and nonchanneled scaffolds w ith  moduli 
of 0.251 ±0.011 and 0.268 ±0.048 MPa respectively (p = 0.49). No 
significant difference in overall scaffold porosity  w as determ ined 
(72 ± 1 vs. 70 ± 3%, 500 pm  channeled and nonchanneled respec­
tively, p = 0.30). EM im aging of individual sheets revealed th a t they 
w ere sim ilar to the p a tte rn  o f the ir substra te  (Fig. 5). The pitch 
m easured from  EM images was 871 ± 24 pm . The larger channels 
w ere m easured to be 489 ± 37 pm  w ide, and the sm aller channels 
w ere m easured to be 205 ± 8 pm  wide. EM imaging of the  scaffold 
cross-sections did no t obviously reveal the presence of channels. 
The scaffolds w ere  excised from  the fram es a fter lam ination, and 
cut in half for testing. The final scaffold dim ensions w ere 
6 x 16 mm.
3.2. Hydraulic permeability
Hydraulic perm eability  w as assessed using th ree  different chan­
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therefore, the  shear stress associated w ith  perfusion in channeled 
scaffolds m ay be m uch less th a n  in nonchanneled  scaffolds. Chan­
neled scaffolds m ay resu lt in low er local shear stresses during  per­
fusion, w hich m ay then  be responsible for conditions m ore 
am enable to cell a ttachm ent, proliferation and survival. During 
perfusion of a nonchanneled scaffold, the  cells m ay experience 
higher shear s tresses th a t ham per a ttachm ent, proliferation or sur­
vival, or a com bination  o f these.
Cellular d istribu tion  uniform ity w as significantly affected by 
culture conditions, bu t surprisingly not by scaffold configuration. 
Scaffolds w ith  and w ithou t channels had no recognizable change 
in cell uniform ity in sp ite  o f the  large difference in cell num ber. 
This seem s to indicate th a t the  perfusion of nonchanneled scaffolds 
creates su itable  conditions for cell survival uniform ly w ith in  the 
scaffold. However, channels m ay affect cell a ttachm ent, prolifera­
tion or nu trien t diffusion, o r a com bination of these.
These studies w ere  perform ed using m esenchym al stem  cells. 
Constructs w ere conditioned w ith  FBS proteins in order to enhance 
cell adhesion. The flow rate  for seeding and perfusion w as based on 
nom inal lite ra tu re  values and system  lim its; how ever, these  vari­
ables may have profound effects on the  cell uniform ity  and cell 
density  w ith in  the  engineered constructs. The system  th a t is de ­
scribed in this paper can be used to  explore th e  effect o f flow rate 
on m any different cell types. M oreover, different conditioning pro­
cedures may be utilized, and the ir effects on construct density  and 
uniform ity can be evaluated.
5. Conclusion
In th is paper we report the  use o f perfusion in thick tissue con­
structs to enhance cell d is tribu tion  and increase cell density. We 
discovered that, in addition  to perfusion, the  presence o f perfusion 
channels in the  scaffolds has a significant effect on cell density  and 
d istribution  independen t of seeding and perfusion culture condi­
tions. This finding provides additional insight in to  the role of chan­
nels and netw orks to seed and susta in  in vitro tissue constructs.
O ur ability  to  seed, grow  and m ain tain  engineered tissue  is lim ­
ited by diffusional g rad ien ts  across sections o f tissue th icker than  a 
few 100 (.im. In native tissue this is overcom e w ith  vascularized 
netw orks. In cultured tissue, how ever, vascular netw orks are not 
alw ays p resen t o r even desired. W e presen t a m eans to engineer 
and specify channel geom etry  in 3-D scaffold m aterials as a design 
variable th a t can play an im portan t role in the  u ltim ate  s truc tu re  
and function of engineered  tissue. This design capability  provides 
engineers w ith  the  ability to m anipulate  the  environm ental condi­
tions as w ell as the  flow, perfusion and clearance o f thick 3-D con­
structs. Scaffold perfusion requires specialized b ioreactors th a t can 
house, pro tect and provide flow to the  scaffold perfusion netw ork. 
Because of the  in tim ate  relationship  betw een perfusion scaffolds 
and bioreactors, these  tw o elem ents should be designed as a sys­
tem  w ith  the  required specifications d irected  not only tow ards 
the  final application but also to the cu ltu re  environm ent.
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Appendix A. Figures with essential color discrimination
C ertain figures in this article, particularly  Figures 4 and 6 -9 , 
are difficult to in te rp re t in black and w hite. The full color images 
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CHAPTER 5
MSC COCULTURE INCREASES TISSUE STIFFNESS IN THREE­
DIMENSIONAL CARDIAC FIBROBLAST MODEL
5.1 Abstract
Cardiac fibroblasts (CFb) are responsible for controlling passive cardiac stiffness 
through extracellular matrix (ECM) synthesis, degradation, and modification. 
Maladaptive cardiac remodeling leads to heart failure through a series of structural 
changes to the heart. These structural changes are effected through CFb-mediated 
changes in passive stiffness. Mesenchymal stem cell (MSC) therapy is promising 
treatment for heart failure; however, the mechanism behind efficacy of MSC treatment in 
animal models is poorly understood. It is hypothesized that MSC interaction with CFb 
can prevent or reverse maladaptive remodeling; however, the model systems that exist to 
test this hypothesis rely on assessment of protein expression to indirectly assess CFb- 
mediated changes in stiffness. Here we describe the design and validation of 3D tissue 
model that allows direct assessment of fibroblast mediated changes in stiffness. A 
perfusion culture platform is described that can sustain a uniform distribution of CFb in a 
porous polyurethane substrate that is 1 mm thick. After cell culture, tensile testing was 
used to evaluate CFb-mediated stiffness. MSC were cocultured with CFb for 10 days.
MSC coculture resulted in a significant increase in construct stiffness. Histological 
analysis showed MSC distributed throughout the coculture samples and an increase in 
type III collagen in coculture samples.
5.2 Introduction
Heart failure (HF) is a chronic condition that constitutes a major socio-economic 
burden to national healthcare systems, and a significant personal burden to families and 
individuals. Many common cardiovascular diseases including infarction, hypertension, 
valvular diseases, and congenital heart disease share HF as the end stage outcome [1]. 
Rates of HF are increasing in developed countries due to longer life-spans and increased 
likelihood of surviving of acute myocardial injury (primarily infarction) [2]. Studies of 
the biomechanical response of the left ventricle to myocardial infarction have identified 
two phenomena that lead to heart failure: (1) ventricular wall expansion in the infarct 
region (i.e., stretching) and (2) infarct-induced fibrosis of remote tissue. These two failure 
mechanisms both initiate and sustain a progressive pathologic process that ultimately 
results in deleterious structural and functional changes to the heart [3, 4]. These changes, 
termed maladaptive remodeling, are caused by abnormal myocardial stress patterns and 
cardiac fibroblast (CFb) mediated ECM remodeling [5]. In general, maladaptive ECM 
remodeling leads to undesirable passive mechanical properties that decrease cardiac 
output. Infarct expansion caused by insufficient passive stiffness leads to heart failure 
through increased wall stress on the surviving myocytes, absorption of the mechanical 
energy of contraction through dyskinesis of the injured region, and decreased ejection 
fraction [5]. Diastolic heart failure, on the other hand, generally leads to increased passive
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stiffness due to fibrosis which prevents proper filling of the ventricle. Clinically, 
ventricular remodeling is a primary indicator of adverse outcomes such as chronic heart 
failure and death [6].
Cardiac fibroblasts (CFb) and acute phase inflammatory cells such as neutrophils 
and macrophages are jointly responsible for wound healing after MI. Due to chronic 
persistence of activated CFb in the heart after MI the long-term successful recapitulation 
of cardiac function after the initial insult is largely dependent specifically on the activity 
of CFb [7]. Stiffness is an important functional performance characteristic of the heart, 
and changes in stiffness are regulated by a precise balance of ECM degradation, synthesis 
and modification. Upon infarction, CFb expression and zyomgenic release of matrix 
metalloproteinases (MMP) has been shown to increase dramatically [8]. The activation 
of quiescent CFb and upregulation of MMP expression results in a local and significant 
degradation of collagen. Takahashi et al. demonstrated that within 3 hrs after infarction, 
50% of the collagen in the infarct region was degraded in rats [9]. Increased MMP 
activity and resultant decreases in the collagen volume fraction in the heart have been 
correlated with ventricular dilatation and systolic dysfunction [10]. It has been 
hypothesized that this decrease in collagen volume fraction results in decreased stiffness 
of the ventricle, and promotes infarct expansion. In an apparent paradox, while MMP are 
mobilized to degrade the ECM, it has been shown that CFb simultaneously increase 
collagen production after infarction [11]. In addition to ECM synthesis and degradation, 
CFb also modify matrix stiffness through production and secretion of lysyl oxidase 
(LOX). LOX is responsible for cross-linking collagen, and studies have correlated 
increases in collagen cross-linking with increases in apparent myocardial stiffness
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without necessarily a change in collagen content [12, 13]. The role of the CFb in ECM 
regulation makes this cell type the key determinant of passive tissue stiffness and 
therefore maladaptive remodeling after MI.
The complex biologic and mechanical impetus of maladaptive remodeling makes 
it a challenging pathology to treat. Medical device and pharmacologic treatments are used 
to provide palliative care and minimize cardiac remodeling, but are generally unable to 
reverse its course [4]. Heart transplantation remains the most effective method for 
treating maladaptive remodeling but is limited by a persistent shortage of donors. 
Recently, cardiac cell therapy has shown inconclusive yet promising results that may lead 
to a new treatment to prevent, and even reverse maladaptive cardiac remodeling [14, 15].
Cell therapy utilizes exogenous cells to stimulate cardiac regeneration. Recently 
the cardiac cell therapy paradigm has shifted largely away from replacement of 
myocytes, to cytoprotective and regenerative support of cardiac function [16, 17]. 
Utilization of mesenchymal stem cells (MSC) in animal models has been shown to be 
effective at preventing maladaptive postinfarction remodeling [18, 19]. Moreover, the 
low immunogenicity of MSC allow the use of allogenic donor cells and potential for 
proprietary expansion methods of MSC make this cell type a possible candidate for 
commercialization [20].
The mechanism behind MSC therapy is not fully understood. This lack of 
mechanistic understanding becomes significant in light of early human clinical trials. A 
meta analysis of 13 clinical trials with a total of 811 patients revealed that MSC therapy 
did not improve postinfarction remodeling [20]. Differences in cell therapy in human 
trials have been attributed to variation in processing methods of therapeutic cells, dosage,
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and timing of delivery [20]. The multipotency of stem cells, while one of their strengths, 
also presents a significant hurdle. Different processing techniques can result in essentially 
different types of cells, even if they were identical to begin with. Appropriate dosing 
requires that both the safety and efficacy associated with various therapeutic dosages are 
known. The dynamic nature of maladaptive remodeling means that timing of cell therapy 
treatment is critical. Treatments that decrease cardiac tissue stiffness may be appropriate 
to prevent fibrosis, but if given too early, these treatments can cause infarct expansion or 
even cardiac rupture. Further mechanistic understanding will define parameters that can 
help move cell therapies from the trial phase to standard treatment in the clinic.
Current approaches to understanding MSC and CFb interactions have typically 
relied on cell culture experiments using tissue culture plastic. However, these studies are 
unable to directly correlate MSC treatment with CFb mediated changes in stiffness. We 
hypothesized that a 3D cell culture platform would allow us to investigate the effect of 
MSC coculture with CFb on changes in cell / scaffold composite stiffness. Here, we 
describe development of a simple culture platform that allows production of a 3D cell 
culture of CFb. This model allows us to correlate changes in bulk mechanical properties 
based on pharmacologic or stem cell interventions. We validated the utility of the system 
by culturing and evaluating 3T3 fibroblasts. We then utilized this culture platform to 
detect changes in CFb mediated stiffness based on cytokine supplementation and 
pharmacologic intervention. Moreover, this system was used to evaluate changes in 
stiffness with and without MSC coculture. We believe that this type of model will 
accelerate our ability to design treatments that more effectively prevent or reverse 
maladaptive remodeling of the heart.
86
5.3 Materials and Methods
5.3.1 Culture Platform Design
5.3.1.1 Biomaterial Substrate
A nondegradable poly (ether-urethane) (PU) substrate was custom fabricated 
using a sprayed phase separation technique that has been described previously [21]. 
Briefly, a 4% PU dissolved in dimethylacetamide (Thermo Fisher Scientific, Waltham, 
MA) solution was sprayed onto a molded PDMS (VST-50, Factor II, Lakeside, AZ) 
surface with 500 p,m corrugations and laminated with a total of six sheets. The resulting 
material was approximately 1 mm thick with enhanced hydraulic permeability due to the 
aligned corrugations between layers (Fig 5.1B) [22]. It was then die cut into 4 x 29 mm 
units for use in these experiments.
5.3.1.2 Culture Chamber
The culture chamber is comprised of a pocketed polycarbonate base, a 
polycarbonate top plate with inlet / outlet ports, and a platinum-cure silicone gasket 
(durometer 30 A, VST-50, Factor II, see Fig 5.1A). The pocket depth was 1.00 ± .02 mm 
as measured using an automated optical measurement apparatus (Vertex, MicroVu, 
Windsor, CA). The tight depth tolerance is necessary to ensure that (1) the substrate is 
not compressed, changing the effective porosity, and (2) “nonperfusing flow” [23] does 
not occur either above or below the substrate in the pocket . As the gasket is compressed 
between the two polycarbonate plates, it expands inward to gently grip the substrate to 
prevent motion during perfusion. Poisson’s ration (v, measured to be 0.47 for the 
platinum cure silicone used to mold the gasket), and the initial thickness (t) of the gasket
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Gasket dimensions were designed to provide an interference of 0.50 - 0.02 mm. 
This interference was observed empirically to provide sufficient grip to prevent the 
substrate from moving during perfusion at flow rates used in these studies.
5.3.1.3 Reservoir and tubing
A modified 15 ml centrifuge tube serves as the media reservoir (See Fig 5.1 C). 
Peroxide-cured silicone tubing (ID 1/6”, OD 1/8”, Cole Parmer, Vernon Hills, IL) 
couples the opposite side of the culture chamber to a 12 ml disposable syringe (Fisher) 
using standard Luer Lock connectors (Qosina, Edgewood, NY). The tubing geometry was 
designed for oxygen exchange between the media and atmosphere. The gas flux (N) 
based on the permeability of the tubing (p), the atmospheric partial pressure (patm), 
maximum partial pressure of gas in solution (pmedia), and the tubing geometry (ID 
circumference and wall thickness) was calculated as shown below.
(2)
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Based on gas flux (N), atmospheric pressure, the desired gas concentration in 
solution ([C]), and the fluid velocity (V), the necessary length of the tubing (L) can be 
determined by using equation 3:
Lf N  ■ dl 
rci = p  -2-------
L J  atm  t  t  j i  r r iV ■ R ■ T
(3)
A tubing length of 100 mm was determined to allow sufficient gas exchange for 
flow rates less than 1 ml/min. A computer controlled, 10-channel syringe pump was used 
to control the cyclic flow pattern through the cell substrate. The assembled culture 
chamber and centrifuge tube reservoir were sterilized with gas-plasma hydrogen 
peroxide; the tubing and connectors were sterilized with steam.
5.3.2 Cell Sources
5.3.2.1 3T3 Fibroblasts
The murine derived 3T3 fibroblast cell line (passage 5) was thawed from frozen 
stocks. Cells were resuspended in fibroblast culture media (used for both 3T3 and cardiac 
fibroblast culture): Dulbecco’s modified Eagle’s medium (DMEM F-12; Thermo Fisher 
Scientific) supplemented with 10% fetal bovine serum (FBS), 2 nM L-glutamine, 50 
pl/ml streptomycin, and 50 U/ml penicillin (Invitrogen, Carlsbad, CA). Cells were 
centrifuged, the supernatant was removed, the cell pellet was resuspended in fresh 
fibroblast culture medium, and plated on a T-75 flask.
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5.3.2.2 Cardiac Cell Isolation
All animal procedures were performed in accordance with an approved protocol 
by the University of Utah Institutional Animal Use and Care Committee. Ventricular 
cardiac cells were harvested from one-day-old Sprague Dawley rats (Charles River, MA) 
using a protocol and supplies from Worthington Biochemical (Lakewood, NJ). Briefly, 
hearts were aseptically removed and rinsed with calcium- and magnesium-free Hank’s 
balanced salt solution. The hearts were minced to approximately 1 mm3 sections and 
digested in 50 |ig/mL trypsin at 4°C overnight. Further digestion was performed the 
following day with collagenase (1500 units) in Leibovitz L-15 media. Cell suspensions 
were triturated, filtered, centrifuged, and plated in culture medium. Nonadherent cells 
were removed after 2 hrs to enrich the fibroblast population.
5.3.2.3 Mesenchymal stem cells
Single donor human mesenchymal stem cells (MSC; ReachBio Seattle, WA) were 
passaged 2-3, and expression of CD29, CD73, CD105 CD34, and CD45 surface markers 
was evaluated by FACS (flow cytometry performed by manufacturer). Upon arrival, cells 
were thawed and grown to 90% confluence on tissue culture plastic using basal MSC 
medium (ReachBio), and then harvested with 0.05% trypsin-EDTA (Invitrogen, 
Carlsbad, CA) immediately prior to seeding.
5.3.2.4 Preseeding Characterization
Confocal imaging was used to characterize the both the cardiac cell population 
and the MSCs prior to seeding. Adherent cardiac cells and MSCs were plated onto 
separate serum-treated coverslips (n=8 each), incubated for 48 hrs at 37°C, fixed with 2% 
paraformaldehyde overnight at room temperature, and triaged for immunostaining.
5.3.3 Seeding Optimization
Two different cell types were used for seeding optimization: 3T3 fibroblasts were 
used initially, subsequently followed by fibroblast enriched cardiac cell populations 
(CFb).
5.3.3.1 3T3 Fibroblast Seeding
Cells were trypsinized after they reached 90% confluency and 1 x 106 cells in 11 
ml of culture media were loaded into each bioreactor reservoir. Substrates were perfused 
at 1500 mm/min with either PBS only (Fn-) or 5 ug ml-1 of fibronectin in PBS (Fn+) for 
24 hrs prior to use to increase cell attachment. The preconditioning solution was 
removed immediately prior to seeding. Cells were cyclically perfusion seeded from the 
reservoir through the PU substrate at a flow velocity of either 100 mm/min (0.43 ml/min), 
1000 mm/min (4.25 ml/min), or 2000 mm/min (8.50 ml/min) for 120 min (n=3 for each 
flow rate). The substrates were then immediately removed and fixed in 4% 
paraformaldehyde (PFA) overnight and triaged for density analysis. Based on initial 
results, all further samples underwent Fn+ preconditioning as described above.
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5.3.3.2 Cardiac Cell Seeding
New seeding velocities were selected based on output from 3T3 seeding 
optimization. CFb were seeded (0.4 x 106 cells in 11 ml culture medium) onto each 
construct. Three different velocities were evaluated: 1000 mm/min (4.25 ml/min), 2000 
mm/min (8.50 ml/min), and 4000 mm/min (17.00 ml/min). During each experiment, 
samples were removed at 30 min, 60 min or 120 min (n=3 at each time point for each 
flow velocity), fixed in 4% PFA, and triaged for density and distribution analysis.
5.3.4 Treatment Induced Changes in Stiffness
5.3.4.1 Ascorbic Acid Supplementation
To ensure the model was capable of detecting treatment induced increases in 
stiffness constructs were cultured in standard fibroblast culture medium (n=5) and 1 mM 
ascorbic acid supplemented (aa+) medium (n=5). A suspension of 1x106 3T3 fibroblasts 
was loaded into each reservoir with either standard or aa+ media. Cells were perfusion 
seeded at 2000 mm/min (8.50 ml/min) for 2 hrs. Following seeding, the flow velocity 
was decreased to 20 mm/min (0.09 ml/min) for the remainder of the 7 day culture period 
to ensure sufficient gas exchange through the silicone tubing and to decrease long-term 
shear stress. Culture media was changed twice by pumping 90% of the media into the 
reservoir, removing it, and adding fresh media. Following culture, all samples were 
triaged for tensile testing.
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5.3.4.2 Angiotensin Converting Enzyme (ACE) Inhibitor Supplementation
To ensure the model is capable of detecting treatment induced decreases in 
stiffness, constructs were cultured in standard fibroblast culture medium and 0.30 p,g/ml 
N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline (lisinopril, TCI America, 
Portland, OR) supplemented medium. A suspension of 0.4* 106 cardiac fibroblasts was 
loaded into each reservoir with either standard (n=10) or ACE inhibitor supplemented 
medium (n=4). Cells were perfusion seeded at 4000 mm/min (17.00 ml/min) for 2 hrs. 
The flow rate was subsequently decreased to 20 mm/min (0.09 ml/min) for the remainder 
of the 10 day culture. Medium was changed twice during the culture period as described 
above. Following culture, all samples were triaged for tensile testing.
5.3.5 MSC Coculture with CFb
A total of 0.3 * 106 CFb were suspended in 11 ml of fibroblast culture medium 
and seeded on each sample at 4,000 mm/min for 2 hrs. Flow rate following the seeding 
phase was 20 mm/min. Individual samples were removed and triaged for immunostaining 
at 3 hrs and 3 days after seeding. After 3 days, either 0.2 x 106 MSC (n=4) or 0.2 x 106 
CFb (n=3) in suspension were added to the reservoir. These cells were then seeded at 
4000 mm/min for 2 hrs prior to returning to 20 mm/min for the remaining 7 days of 
culture. Medium was exchanged twice per week on all samples. After 10 days of culture, 
samples were removed and triaged for tensile testing and immunostaining.
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5.3.6 Tensile Testing
Tensile testing of samples was performed immediately upon removal of samples 
from the bioreactor. Samples were gripped at a gauge length of 19.1 mm and strained at 
a rate of 1 mm/min to an extension of 40% while monitoring force with a 50 N load cell 
(Instron, Norwood MA). Cross-sectional dimensions of each scaffold were obtained 
using digital calipers and were used to calculate the Young’s tensile modulus of the 
substrate from 10% (to compensate for slight differences in pretension) to 30% extension.
5.3.7 Cell Density and Distribution Analysis
Cell nuclei were stained with 4' ,6-diamidino-2-phenylindole dihydrochloride 
(DAPI) for 30 min in 0.1% triton X-100 prior to imaging. An Olympus FV 1000 confocal 
microscope (Olympus, Center Valley, PA) with a 4X objective and motorized stage was 
used to obtain mosaic images of the entire substrate surface. Mosaic images were stitched 
using a stitching plugin for Fiji [24], and were cropped and filtered for noise using Fiji 
(NIH, Bethesda, MD). Cellular density and distribution were assessed using a method 
modified from Tang and colleagues [25]. Briefly, custom Matlab code was applied to the 
images to sum the number of DAPI positive pixels along the length of the substrate. The 
number of DAPI positive pixels was normalized to the total number of pixels and 
averaged along the length of the substrate. This value is reported as the relative cell 
density. The cell uniformity is quantified by measuring the standard deviation of DAPI 
positive pixels along the length of the substrate. The standard deviation of pixel intensity 
along the length of the substrate was normalized to the intensity to provide a relative
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uniformity index, therefore, a lower uniformity index represents a more even distribution 
of cells throughout the substrate.
5.3.8 Immunostaining
Samples were divided into two groups for immunostaining: (1) Cardiac cell 
phenotyping, and (2) ECM characterization. The cardiac cell phenotyping group was 
trilabeled with vimentin to identify nonmyocyte cardiac cells (mostly fibroblasts), a- 
smooth muscle actin (SMA) to distinguish activated myofibroblasts (vimentin and SMA 
positive), and DAPI to identify nuclei. When cocultured with MSC, this group was 
quadlabeled with human nuclei antibodies (HNA) to differentiate between human MSC 
and rat cardiac cells. ECM was characterized through antibody staining for collagen type 
III and DAPI. Controls for autofluoresence and nonspecific secondary adsorption were 
run to control for nonspecific fluorescence.
All labeling was performed on a laboratory platform rocker at room temperature 
(Thermo Fisher Scientific). SMA, vimentin, and HNA antibodies were diluted in 
blocking solution consisting of 4% goat serum (Invitrogen) and 0.5% Triton X-100 
(Fisher Scientific) diluted in PBS. Collagen type IIII is an extracellular marker, and was 
therefore diluted in the same solution without triton X-100. Rinsing was performed 
between all incubation steps and included three PBS wash outs, and three 15 min PBS 
rinses.
For cardiac cell phenotyping, samples were incubated for 18 hrs with mouse 
IgG2a anti-a-SMA (1:200 ^g/mL in blocking solution; A5228; Sigma-Aldrich, St. Louis, 
MO), followed by 6 hrs with goat anti-mouse IgG2a-conjugated Alexa Fluor 633 (1:200;
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A21136; Invitrogen), 16 hrs with mouse IgG1 anti-HNA (MSC coculture samples only; 
1:400; MAB1281; Millipore-EMD, Billerica, MA) followed by 6 hrs with goat anti­
mouse IgG1-conjugated Alexa Fluor 488 (1:200; A21121; Invitrogen), 16 hrs with mouse 
IgG1 anti-vimentin-conjugated with Cy3 (1:20; C9080; Sigma-Aldrich), and 3 hrs with 
DAPI (1:400; Sigma-Aldrich).
For ECM characterization, samples were incubated for 16 hrs with mouse IgG1 
anti-type I collagen (1:200; C2456; Sigma-Aldrich) followed by 6 hrs with goat anti­
mouse IgG1-conjugated Alexafluor 555 (1:400; A21127; Invitrogen), 16 hrs with mouse 
IgM anti-type III collagen (1:200; MAB2515; Millipore EMD) followed by 6 hrs with 
goat anti-mouse IgM-conjugated Alexa Fluor 633 (1:400; A21046; Invitrogen), and 3 hrs 
with DAPI (1:400; Sigma-Aldrich). All samples were stored in PBS at 4 °C.
5.3.9 Imaging
Imaging was performed on a confocal microscope (Zeiss LSM 5 Duo, Zeiss, Jena 
, Germany). For ECM characterization and images collected on glass coverslips, single 
image slices were obtained using a 10X objective and pinhole of 1.83 airy units. For 
fibroblast phenotyping on the substrate, image stacks were collected over 50 microns 
with a 2.5 micron step size using a 40X objective. The image stacks were z-projected 
using Fiji (NIH) and filtered for noise.
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5.3.10 Statistics
Data are reported as averages ± standard deviation. Student t-tests were used 
evaluate significance (a=0.05). For tensile studies, t-tests were used to evaluate 
differences in mean stiffness.
5.4 Results
5.4.1 Culture Platform
Pocket depth in all culture chambers was observed to fall within 1.00 ± 0.02 mm 
using an optical dimensioning system. The porosity of the substrate was 79.6 ± 1.5%. 
Dry substrate thickness was measured to be 0.99 ± 0.04 mm. The dry tensile modulus 
was 231.3 ± 27.6 kPa.
5.4.2 Cell Phenotyping
Cardiac cell populations were observed to stain positive for vimentin, and highly 
positive for a-SMA. Morphologic assessment confirmed that >90% of cells observed 
appear to be fibroblasts (Fig 5.3). Flow cytometry confirmed MSC were positive for 
CD29, CD73, and CD105 and negative for CD34, and CD45.
5.4.3 Seeding Optimization
Preliminary seeding optimization was performed first using 3T3 Fb to narrow 
seeding parameters and to evaluate fibronectin surface preconditioning. A significant 
increase in cell density was observed as the flow rate increased (Fig 5.4). Further,
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fibronectin coating resulted in a higher mean cell density at each flow velocity; however, 
this difference was only significant at a flow rate of 2000 mm/min (Fig 5.4). Based on 
these results, all further samples were preconditioned with fibronectin.
A second seeding optimization was performed with CFb to corroborate the results 
of the 3T3 study, and to evaluate seeding duration. At 1000 mm/min, cells were 
qualitatively observed to be primarily distributed around the inlet and outlet (Fig 5.5D). 
Image analysis confirmed that at 30, 60 and 120 min seeding durations, the standard 
deviation of cell distribution was significantly lower for flow velocities of 4000 mm/min 
compared to 1000 mm/min (p<0.05, Fig 5.5A-C).The mean cell density when seeded at 
4000 mm/min was highest after 120 min (p<0.05, Fig 5.6A). Moreover, after 120 min the 
mean cell density was higher for samples seeded at 4000 mm/min than samples seeded at 
1000 or 2000 mm/min (p<0.05, Fig 5.6B).
5.4.4 Treatment Induced Changes in Stiffness
3T3 fibroblasts were seeded and cultured with standard culture medium, and 
ascorbic acid (aa) supplemented medium to validate the model’s ability to detect 
treatment induced increases in stiffness. The tensile stress was approximately linear from 
10% to 30% strain (data not shown). Acellular controls (cultured identically, without 
cells) had a modulus of 147.6 ± 10.2 kPa (n=5). Samples cultured with standard media 
had a higher average modulus of 161.7 ± 8.1 kPa (p=0.027, n=5). Samples cultured with 
aa+ medium had a significantly higher modulus than untreated constructs (178.1 ± 6.8 
kPa, p=0.004, n=5, see Fig 5.7A).
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CFb response to an angiotensin converting enzyme (ACE) inhibitor was used to 
evaluate the capability of the system to detect treatment-induced decreases in stiffness 
using cardiac fibroblasts. Compared with acellular substrates, the stiffness of CFb seeded 
constructs was significantly higher at 184.2 ± 11.6 kPa (p=0.008, n=10). The stiffness of 
ACE inhibitor (lisinopril) treated constructs was significantly less than untreated CFb 
substrates at 156.3 ± 12.55 kPa (p=0.007, n=4) but not significantly different from 
acellular samples (Fig 5.7B). Imaging and image analysis revealed no significant 
difference in cell distribution or density between standard and ACE inhibitor 
supplemented samples (data not shown).
5.4.5 Coculture of CFb and MSC
Coculture of CFb and MSC resulted in a significantly higher tensile modulus 
when compared to CFb only samples (p=0.032, Fig 5.8). The number of CFb increased 
over the duration of culture, with maximum number of cells observed on day 10 (Fig 5.9, 
A-C). In coculture samples, human MSC were observed to be distributed throughout 
groups of the CFb population (Fig 5.9D). Very little collagen type III was observed at 
t=3hrs. Type III collagen was observed to increase in abundance at t=3 days and again at 
t=10 days (Fig 5.10 A-C). Very low levels of type I collagen were detected at all time 
points (E-H). Moreover, compared to CFb only samples, coculture samples appeared to 
have higher levels of type III collagen (Fig 5.10 C-D).
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5.5 Discussion
The complexity of fibroblast-mediated changes in passive stiffness makes indirect 
assessment of stiffness using histological or biochemical techniques extremely 
challenging. Here, we developed and validated a 3D cell culture model for direct 
evaluation of CFb-mediated changes in stiffness in response to pharmacologic or cellular 
treatment.
Here, flow is presented in terms of fluid velocity, mm/min. Fluid flow has been 
shown to affect fibroblast expression of MMP, TIMP, and migration [26]. Fibroblast 
mechanotransduction of fluid flow occurs as a surface phenomenon where local shear 
stresses interact with ECM and integrins resulting in intracellular signaling through the 
mitogen activated protein kinase pathway [27]. Since, shear stress estimations of 
composite cellularized biomaterials are dependent on local fluid velocities rather than 
bulk flow [27, 28]. We believe that for this perfusion system, reporting fluid velocity is 
more pertinent than volumetric flow.
We chose fluid velocities for the seeding phase and culture phase based on initial 
work with both 3T3 Fb and CFb. Corresponding data regarding appropriate flow for 
mixed cardiac cell populations vary considerably. Madihof et al. tested cyclic fluid 
velocities ranging from 6 - 60 mm/min using a population of cardiac cells that had been 
enriched for myocytes [29]. They determined that the fastest velocity tested (60 mm/min) 
resulted in the highest seeding efficiency. Moreover, they determined that seeding 
efficiency was slightly higher after 2 hrs of seeding compared to one. Our results agree 
with the seeding time of 2 hrs being slightly better than 1 hr. However, the flow rates 
used during seeding in this work are many times faster than previous studies. Fibroblasts
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attach to surface in 10-30 min, while myocytes can require hours to attach to synthetic 
polymer surfaces [30]. In these studies, perfusion rates below 2000 mm/min resulted in 
inhomogeneous attachment of CFb throughout the substrate (Fig 5.4A-C). At a velocity 
of 1000 mm/min, most of the CFb were located immediately below the inlet (Fig 5.4D). 
It appears that CFb cell populations may require significantly higher seeding velocities 
than myocyte-containing cardiac cell populations likely attributable to the difference in 
rate of attachment of the two cell types.
The qualitative appearance of cells in the polyurethane substrate was different 
from cells cultured on glass coverslips. It is well known that fibroblast morphology and 
phenotype can be altered by differences in 2D versus 3D substrates, stiffness of substrates 
and substrate chemistry [31-33]. In our experiments, the polyurethane material may be 
preferentially selecting for certain cardiac cell populations although this was not 
specifically examined. The polyurethane material used in these experiments has been 
extensively characterized in its ability to support primary Fb under different culture 
conditions [34-37]. Despite the qualitative differences in cell morphology between the 
glass coverslips and the polyurethane scaffold, we believe it is unlikely that the culture 
conditions are preferentially enriching a nonfibroblast population of cardiac cells. This is 
because primary fibroblasts are known to proliferate on these substrates, the starting 
population contains a high percentage of fibroblasts and our qualitative observations over 
the time course of the experiments provides visual evidence that the fibroblasts have 
proliferated and attached to the polyurethane substrate.
Murine 3T3 fibroblasts were used to evaluate the ability of the culture platform to 
detect treatment-induced increases in stiffness. Previous work has shown that ascorbic
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acid (aa) enables the assembly of ECM proteins [38] and increases stiffness [36]. ACE 
inhibitor treatment, on the other hand, was shown to decrease the stiffness of CFb 
populated constructs after 10 days. This corresponds to the well established role of ACE 
inhibitors in preventing fibroblast mediated fibrosis [39]. Our validation demonstrates 
that the culture platform is capable of observing aa induced increases in stiffness, and 
ACE inhibitor induced decreases in stiffness compared to untreated cellular groups.
MSC and CFb coculture resulted in a significant increase in stiffness when 
compared to cell number controlled CFb only samples (Fig 5.8). HNA staining 
demonstrated that human MSC were present among CFb after 10 days of coculture (Fig 
5.9). We believe that this increase in stiffness is in part due to an increase in type III 
collagen in coculture samples compared to CFb only samples (Fig 5.10 C-D). It is not 
evident from the data whether the MSC contribute to the accumulation of type III 
collagen directly through collagen synthesis, or whether they contribute indirectly 
through paracrine or juxtacrine influence of CFb behavior. One study shows that MSC 
cultured on substrates increased type III collagen production and stiffness in response to 
mechanical stimulation [40]. It is likely that shear stress in the model could contribute to 
mechanical stimulation of MSC, which would support the hypothesis regarding the direct 
role of MSC in collagen synthesis. This hypothesis is further supported by studies that 
have shown in vitro paracrine signaling of MSC downregulates CFb expression of type 
III collagen [41]. Future studies evaluating the species origin of the type III collagen 
could help further elucidate the direct and indirect contributions of MSC to the observed 
changes in stiffness. The lack of type I collagen type is surprising, and may be due to 
collagen passing into the culture media before it is able to assemble as has been observed
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in 2D cell culture [42]. The culture medium did not have ascorbic acid, which is 
necessary for assembly of mature collagen fibers which may help to explain why little 
type I collagen was observed [43].
This model is limited in its ability to detect changes in stiffness by the use of a 
nondegradable substrate. The observed changes in bulk stiffness are due to a complex 
interaction of interstitial fluid flow, cytoplasmic rearrangement, and bending, flexing, and 
elongation of intra and extracellular filaments. Modulus of collagen molecule ranges 
from 2.9 to 9.0 GPa as measured by X-ray diffraction technique [44]. Collagen fibers are 
considerably softer, measured at 0.7-3.7 MPa using tensile stress-strain analysis [45]. In 
the myocardium, it appears that perimysial collagen fibers are not elongated during strain, 
but rather undergo helical bending and uncrimping that accounts for the majority of the 
measured stiffness in the myocardium [46]. In a mathematical model these forces have 
been calculated to be on the order of 135-160 MPa [46]. In addition to collagen, several 
groups have demonstrated that cytoskeletal filaments of fibroblasts themselves can exert 
tractional forces in the range of tens of nanonewtons per focal adhesion that resist 
extension and potentially contribute to bulk stiffness [47, 48].
The general rule of mixtures states that the overall modulus can be approximated 
by summing the product of the modulus and volume fraction of each constituent. This 
approximation provides an upper bound for stiffness by modeling the individual elements 
in series. The general rule of mixtures assumes that coupling of all elements is ideal and 
that no interfacial failure occurs. The inverse rule for mixtures, on the other hand, 
assumes no interfacial coupling between the different material constituents, and provides 
a lower bound for the overall stiffness by modeling a parallel alignment of the various
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elements comprising the material. In reality, the modulus of the cellularized substrate 
falls somewhere between the upper bound determined by the rule of mixtures, and the 
lower bound determined by the inverse rule. The degree of coupling of cells and ECM to 
the substrate is the primary determinant of whether the material stiffness approaches the 
upper or lower bound for tensile stiffness.
Cells serve as the primary binding element that couples matrix components and 
internal cellular skeletal filaments to the substrate. Focal adhesion complexes attach cells 
to proteins adsorbed to the surface of the substrate as well as to surrounding matrix 
elements. The adhesion of 3T3 fibroblasts to fibronectin coated silicon has been 
measured to be approximately 450 dynes/cm2 (45 Pa) [49]. Uncoupling of the cellular 
material from the substrate will obscure cellular contributions to stiffness. Indeed, this 
model is only capable of assessing bulk changes in stiffness; local uncoupled 
contributions to stiffness are overshadowed by the modulus of the substrate. Moreover, 
measured against a constant, and relatively large stiffness of the substrate itself, the 
ability of this system is limited in its ability to detect cell-mediated changes in stiffness 
that are too soft to be detected over the baseline stiffness of the substrate (~150 kPa). 
Despite these limitations, the ability to measure bulk stiffness gives insight a tissue-level 
functional property that, in vivo, directly influences the performance of the heart.
Another limitation is the use of vimentin to identify fibroblasts from the cardiac 
cell population. While myocytes do not stain positive for vimentin, this marker also 
identifies endothelial and neuronal cells found in the heart. However, since >90% of 
nonmyocytes in the heart are fibroblasts, until more specific methods for fibroblast 
identification are established, vimentin staining coupled with cyto-morphologic
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evaluation is generally accepted as a method to identify fibroblasts in mixed cardiac cell 
populations [50] .
Another limitation to this study is the use of human MSC with rat CFb. There is a 
high degree of conserved function between human and rat CFb; however, there are 
differences including expression of MMP-1, and integrin expression in response to 
angiotensin II. In this study, the species difference allowed for differentiation of human 
and rat cells through antibody labeling. For future studies using human CFb, alternative 
methods for differentiating the cells will be required. In addition, we believe that future 
application of the model described here can be used to rapidly identify MSC 
preconditioning or modification that will lead to positive outcomes in vivo.
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Fig 5.1. Culture platform schematic. (A) An exploded view of the culture 
chamber. This view describes the assembly of each culture cassette including the 
substrate and silicone gasket that ensure perfusing media flow. (B) Cross section of 
culture cassette with arrows to demonstrate the flow path.
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Fig 5.2. Image processing method. (A) Individual DAPI images were collected 
and stitched together to form mosaic images (B). (C) Column summing of DAPI positive 
pixels along the length of the tissue was used to evaluate cell distribution along the length 
of substrate. (D) Moving average (solid-black), overall mean (solid-blue) and overall 
standard deviation (dashed-red) were calculated to quantify cell density and uniformity.
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Fig 5.3. Initial phenotyping of cardiac cell population. CFb were identified 
morphologically from vimentin positive cells. Cardiac cells at t=0 highly expressed a- 
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Fig 5.4. 3T3 Fb density with different seeding velocities and substrate coatings. 
Cell density increased after 2 hrs of seeding using 3T3 Fb with fibronectin 
preconditioning (Fn+) compared to without (Fn-). Further, density of 3T3 cells increased 
as perfusion velocity increased from 100mm/min to 2000 mm/min. *p<0.05 ** p<0.01. 
n=3 for each group.
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Fig 5.5. CFb uniformity with different seeding velocities and duration. CFb were 
seeded onto substrates at 1000 mm/min (4.25 ml/min), 2000 mm/min (8.50 ml/min), and 
4000 mm/min (17.00 ml/min). The standard deviation of cell distribution was assessed 
for each flow velocity at 30 min (A), 60 min (B), and 120 min (C, n=3 for each velocity 
and duration). *p<0.05 when compared to 1000 mm/min velocity. (D) Representative 
image of a substrate after 2 hrs of seeding at 1000 mm/min with cardiac fibroblasts. 
Distribution is highly nonhomogeneous with more cells located in the inlet region. (E) 
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Fig 5.6. Mean CFb density with different seeding velocities and duration. (A) 
Mean cell density of cardiac fibroblasts seeded at 4000 mm/min for 30, 60 and 120 min 
(n=3 each). *p<0.05 from 30 min and 60 min seeding durations. (B) Mean cell density of 
cardiac fibroblasts seeded at 1000, 2000, and 4000 mm/min for 120 min (n=3 each). 




Fig 5.7. Treatment induced changes in stiffness. (A) Tensile modulus of acellular, 
3T3 Fb in standard culture medium, and 3T3 Fb in aa supplemented medium after 
perfusion culture (n=5 each). (B) Tensile modulus of acellular, Cardiac Fb in standard 
culture medium, and cardiac Fb in ACE inhibitor (lisinopril) supplemented medium after 








Fig 5.8. Tensile modulus of MSC coculture constructs. Elastic modulus of CFb 
cocultured with MSC was significantly higher than cell number controlled constructs 
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Fig 5.9. Cell characterization during culture. Samples were removed and imaged 
after 3hrs (A), 3 days (B) and 10 days (C-D). CFb only samples (A-C) were labeled for a- 
SMA, vimentin, and cell nuclei. CFb-MSC coculture samples were labeled additionally 
for human nuclei (HNA) to identify MSC (see arrows in D). Scale bars are 50 p,m
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Fig 5.10. Collagen labeling during culture. Type III collagen levels appeared to 
increase over time (A-C). MSC coculture increased levels of type III collagen compared 
to CFb only samples (C-D). Dotted white line marks the edge of the substrate in (B). 
Scale bars are 100 ^m.
CHAPTER 6
CONCLUSION AND FUTURE DIRECTIONS
6.1 Summary and conclusions 
In Chapter 3, methods for fabricating a biocompatible substrate with engineering 
control over stiffness, anisotropy, and porosity were described. This process was 
automated using a three axis computer controlled spray system. The material used to 
fabricate the substrate is a nondegradable poly (ether-urethane). Previous work describes 
methods for processing polyurethanes into porous cell scaffold materials [1] and the use 
of a sprayed phase separation technique [2, 3]. This work expanded upon current 
approaches to sprayed phase separation in two ways: (1) the effect of nonsolvent ethanol 
concentration on stiffness, porosity, and microarchitecture was evaluated, and (2) a 
postspray elongation technique was developed to introduce anisotropy. Prior to this work, 
a noteable dipped phase separation technique had been developed by Papenburg et al. [4]. 
This group evaluated several different alcohol classes and concentrations ranging from 
0% to 12.5%. Their work inspired the use of alcohol in the nonsolvent in this dissertation. 
Based on their results we utilized ethanol in the nonsolvent and expanded the nonsolvent 
concentration from 0% to 85%.
Moreover, in this work we demonstrated that through postspray elongation this 
material can be engineered to serve as a static 3D architectural map for fibroblast 
orientation. One approach to recapitulate cardiac structure and function is to match 
substrate anisotropy to native cardiac structure. In the first phase of this work, variation in 
postspray elongation was shown to be correlated with the anisotropy ratio based on 
mechanical testing. Further, experiments with 3T3 fibroblasts demonstrated that the 
aligned microarchitecture of the substrate influenced fibroblast alignment within the 
material. While this technique was not employed in later phases of this work, this is an 
important technique that broadens the capability of the methods developed in Chapter 3. 
The control over mechanical properties through postspray elongation and nonsolvent 
composition established in this phase of the work was critical for later work where this 
material was shown to have sufficient elasticity to allow detection of cell-mediated 
changes in stiffness after 10 days of cell culture.
One practical outcome of this phase of research is a method to robustly fabricate 
porous substrates with high fidelity and control over porosity and mechanical properties. 
The substrates used in Chapters 4 and 5 relied on the methods developed in this phase of 
the work. In 2012, 8 batches of substrates (60 substrates from each batch) were 
fabricated. The porosity and stiffness were inspected from each batch before the 
substrates were released for use in experiments. Porosity varied by only 2.0% in all 
batches (over 450 substrates). The robust process used to fabricate the cell scaffold 
material described in Chapter 3 is a necessary feature of any scaffold that aspires to span 
the gap between 2D cell culture and animal models [5].
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In Chapter 4, a lamination procedure is described that builds channel-like features 
for anisotropic permeability into composite substrates with variable thicknesses. Prior 
work described dipped phase separation micromolding techniques [4]. This technique 
resulted in patterned surfaces of porous materials. The research described here expanded 
on existing techniques by laminating multiple micropatterned sheets to form enclosed, 
three-dimensional features within the substrate. The structural features of these substrates 
were evaluated for both qualitative architecture, and performance characteristics. A 
media perfusion system was built and the effect of media perfusion on both channeled 
and nonchanneled substrates was evaluated. Previous studies with cell culture have 
highlighted the need for convective media transport to supplement diffusion to maintain 
viability of 3D tissues [6-9]. The unintended consequence of perfusion in cell culture is 
cellular damage and phenotypic shift due to shear stress of the moving fluid. Both cardiac 
cells (primarily myocytes, however, Fb are responsive as well) and MSC are highly 
susceptible to shear stress-induced damage [10-12]. Moreover, depending on substrate 
microarchitecture, media flow can “wash” cells off the substrate surface resulting in 
decreasing cell density over time [13]. Approaches to shielding cells from unnecessary 
shear stress through scaffold architecture hold promise for development of the next 
generation of 3D cell culture platforms [14]. By designing a substrate with anisotropic 
hydraulic permeability, we demonstrated that we could significantly increase cell density 
of MSC after perfusion culture. This result helps establish the use of aligned flow 
channels to favorably modify media convection through the substrate. Since this work 
was originally performed, numerous approaches to designing channels into 3D substrates 
have been proposed [15-18].
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The work contained in Chapter 5 describes modifications to the perfusion culture 
platform to yield individual culture cassettes. These perfusion cassettes are considerably 
easier to fabricate and use compared to the initial perfusion system descroibed in Chapter
4. Validation of the new culture platform was performed using murine 3T3 fibroblasts. 
Once functional perfusion parameters were determined, CFb were seeded and cultured on 
the substrate. An ACE inhibitor and TGF-P were used to validate that treatment induced 
changes in stiffness could be detected using this system. Following these experiments, 
MSC were cocultured with CFb for 10 days. Significantly, we observed that despite 
increased cell density, MSC coculture with cardiac fibroblasts did not increase stiffness 
when compared to controls. The major conclusion from this phase of work is that 
unmodified MSC should not be used to influence cardiac fibroblast mediated stiffness. 
Future utilization of this model will allow evaluation of modified MSC in treating heart 
failure. While MSC therapy is a promising new treatment for heart failure, it is still 
unclear what mechanism is responsible for restoring cardiac function in animal models
[19]. It has been hypothesized that MSC treatment may have an influence on fibroblast- 
mediated stiffness, but prior to this work direct measurement had not been attempted. 
Previous work has had conflicting results regarding the effects of MSC coculture on 
cardiac stiffness; one study implies that MSC cause increased degradation of ECM 
through increased MMP production [20], while another suggests that MSC coculture 
suppresses MMP production and therefore decreases ECM degradation [21]. Many 
groups have focused on MSC preconditioning or genetic modification [22-24]. Further, 
clinical MSC isolation kits vary significantly and potentially “modify” MSC enough to 
cause divergent clinical outcomes [25]. The work presented here supports a growing
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body of evidence that unmodified MSC may not have significant effects on cardiac 
remodeling. Despite this negative finding, the platform developed to evaluate MSC-CFb 
coculture still holds considerable promise to evaluate modified MSC interactions with 
CFb. Whatever treatment is developed for maladaptive cardiac remodeling, the platform 
developed here can provide crucial insight into treatment-induced changed in stiffness. 
Further, common molecular biology techniques can be employed to gain insight to 
expression of proteins that are related to stiffness. Application of this insight may directly 
influence clinical implementation of cardiac cell therapy treatments.
6.2 Applications and Future Directions
6.2.1 Mesenchymal Stem Cell Modification
The cell culture model described here has application in preclinical evaluation of 
stem cell interaction with cardiac fibroblasts in 3D. In practice, the use of bone marrow 
derived stem cells requires specific preparation and isolation processes that have yet to be 
standardized [19]. This lack of standardization contributes to one limitation of this 
research -  the status of the MSC used in this experiment is related to their history prior to 
use. It is difficult to directly correlate results from this study to other studies because of 
differences in the treatment of MSC prior to their use. Divergence of the centrifugation 
methods used to separate MSC and passage number has been linked to variation of 
clinical outcomes [25]. Beyond simple processing modifications, some groups have 
demonstrated that genetic modification of MSC can have enhanced therapeutic effects in 
animal models. Lian et al. demonstrated that prostaglandin I synthase transformed MSC 
had higher wall thickness and lower percentages of fibrotic area than unmodified MSC in
mice [22]. Gnecchi and colleagues showed that modification of MSC with the AKT1 
survival gene resulted in production of paracrine signals that significantly decreased 
cardiomyocyte apoptosis when compared to unmodified MSC [24]. Utilization of the in 
vitro model described herein to evaluate treatment induced changes in stiffness effected 
through modified MSC phenotypes will allow optimization of the cell processing and 
preparation techniques that would otherwise be prohibitively difficult and expensive to 
implement in clinical studies.
6.2.2 Dosing and Cell Retention Studies
Another clinical variable associated with implementation of stem cell therapy is 
dosage [19]. Dosage is dependent on two factors: (1) cell retention, and (2) cell activity
[26]. In most cases, the majority of therapeutic cells delivered to the heart are not retained 
in the desired area after 24 hrs [27]. Moreover, vitality of stem cells after implantation is 
often decreased significantly depending on the method of delivery and delivery medium
[28]. The model and techniques described in this work can be used to assess the 
minimum number of therapeutic cells required for positive stiffness outcomes. In Chapter
5, rat cardiac fibroblasts were cocultured with human MSC. We were able to differentiate 
between MSC and fibroblasts using a human specific nuclei stain. Methods described in 
Chapter 5 for quantification of cell distribution and density could be applied to determine 
the ratio of MSC to fibroblast throughout the substrate. In future studies using species 
matched cells, a method described by Radisic and colleagues propose modifying stem 
cells with a genetic indicator (yellow fluorescent protein marker) to differentiate between 
injected cells and “native” cells in engineered tissue models could be employed [29].
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Other groups have used similar transfection approaches to identify MSC injected in in 
vivo models [23, 30]. Expansion of the current model system to include global cell 
tracking techniques will allow preliminary evaluation of approaches aimed at preventing 
stem cells from “washing away.” Retention and survival data coupled with functional 
stiffness changes will help establish a starting point for minimum dosage to be used in 
vivo. This minimum local cell dosage number may then be used as an input for 
determining what delivery techniques can be used to meet this requirement.
In addition to investigating whether stems cells are retained after injection, the 
biomaterial-based model proposed in this work allows interrogation of phenotypic 
changes that occur during 3D fibroblast and MSC coculture. In general, fibroblast surface 
interactions with synthetic materials (and the materials’ relatively high surface stiffness) 
tend to guide them toward an activated “myofibroblast” phenotype [31]. We observed 
that the majority of fibroblast expressed some level of a-SMA, indicative of a 
myofibroblastic phenotype. On the other hand, the fate of MSC after injection is still 
unclear. One study indicates that under certain circumstances, MSC recruited to the heart 
after infarction assume a fibroblast like phenotype [32]. The criteria to fully characterize 
the phenotype of a MSC in a cardiac environment has yet to be determined, and 
constitutes a field of future work necessary to understand the role of MSC in cardiac 
regeneration. An important next step for the model described in this work is to evaluate 
the phenotypic endpoint of the MSC during coculture. Understanding of phenotypic 
changes during coculture will speed design of appropriate stem cell treatment regimens 
and therefore clinical implementation.
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6.2.3 Correlation of Bulk Tissue Behavior with Molecular Biology
Beyond its use as a tool to directly correlate stiffness with cell therapy regimens, 
the fibroblast model here can be used to better understand the molecular mechanisms 
involved with fibroblast mediated stiffness. As described in Chapter 1, fibroblasts 
regulate passive stiffness through a complex balance of ECM synthesis, degradation, and 
modification. Numerous regulatory components have been identified that are produced 
by fibroblasts, however there is considerable ambiguity surrounding the role that they 
play in regulating passive stiffness of cardiac tissue. For example, collagen deposition by 
CFb is generally considered to increase stiffness, however, after infarction in sheep, 
collagen content was shown to increase from ~40 p,g/mg after 2 weeks to ~70 p,g/mg after 
6 weeks. At these same time points, the stiffness of the tissue decreased from 338.5 
g/cm2 at 15% strain in the preferred direction to 115.6 g/cm2 [33]. The complexity of the 
relationship between molecular mechanisms and changes in observed stiffness are of 
paramount importance for heart failure. Several studies have shown that targeted deletion 
or inhibition of certain MMP or MMP inhibitors can prevent cardiac remodeling [34-36]. 
Application of engineered tissue models to understand how suppression, over-expression, 
or deletion of ECM regulatory factors impacts bulk stiffness will open new avenues for 
developing pharmacologic approaches to treating systolic and diastolic heart failure.
Future work using the engineered tissue described here aims to utilize western 
blot techniques to identify changes in protein expression resulting from MSC coculture. 
Methods employed by Mias et al. to quantify MMP expression and activity [20] could be 
could be adapted in a straight forward manner to this culture platform. The primary 
proteins of interest are for rat CFb regulation of ECM are MMP-2, MMP-9, TIMP-3 and
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lysyl oxidase. Following culture, protein will be harvested and isolated, and then 
quantified using western blot techniques. In addition, more detailed qualitative analysis 
of ECM structure can be achieved through electron microscopy, or immunohistological 
approaches [37, 38]. Quantative evaluation of ECM components can be evaluated by 
serial digestion of ECM using matrix specific proteases as described by Tresco and 
colleagues [39].
6.2.4 Culture Platform Modifications
One of the current limitations of the culture platform described in this work is the 
inability to perform online tissue analysis. Lagana et al. have designed a optically 
accessible perfusion bioreactor for online evaluation of engineered microtissues [40]. 
Principles from their work could be simply applied to the culture cassette described here 
to provide optical access to the culture chamber without compromising sterility of the 
construct. The current design of the culture cassette utilizes a polycarbonate base plate. 
This material allows visualization of the substrate during culture. The major challenge, 
however, lies with overcoming limitations in working distances using higher 
magnification (> 10X) objectives. This problem could be approached through a redesign 
of the culture cassette to provide a coverslip “window” into the culture chamber. Further 
redesign of the position of the reservoir will be necessary as well to fit the entire culture 
cassette onto most imaging stages. Confocal microscopy permits visualization 
approximately 100 p,m into the polyurethane scaffold (unpublished observation). Two- 
photon microscopy may increase the achievable imaging depth [41]. Second harmonic 
generation (SHG) allows live imaging of collagen and elastin structure without requiring
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staining [42, 43]. An optically accessible culture chamber will allow real-time evaluation 
of development and changes in extracellular matrix structure as well as cellular 
distribution, density and vitality.
The methods used to fabricate the biomaterial substrate described in this 
dissertation have been optimized, and with the exception the lamination, automated. The 
reproducibility of the substrate has been evaluated over the course of 2 years of 
production. This material has the potential to serve as a foundational component for many 
3D cell culture systems. Further development of the fabrication methods can lead to a 
customizable biomaterial cell substrate that can be made available as a foundational 
starting point for 3D cell culture to a wide variety of research groups.
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APPENDIX
ENGINEERING PRINTS OF PERFUSION BIOREACTOR

REV DESCRIPTION DWN DATE




SIZE DWG. NO. REV
A N/A 01
PART NO: N/A SPEC: N/A 
MODEL FILE: Perfusion bioreactor
SCALE: 1:8 SHEET 1 OF 2
ITEM
NO. PART NUMBER DESCRIPTION QTY.
1 SM17205D Animatic Smart motor series stepper motor 1
2 motor to slide coupler Thomson motor to slide coupler - included with part number MS33LEAL200 1
3 Linear slide platform Thomson linear slide bearing, included with PN: MS33LEAL200 1
4 Syringe clamp-Mounted plnger clamp Custom machined 6061 aluminum 1
5 91239A228 Black Finish Steel button head socket cap  screw M5, McMaster 4
6 Syringe clamp-Threaded plunger clamp Custom machined 6061 aluminum 2
7 57715K38 1 /4-20 x 1 /2" Phenolic three arm knob with threaded stud. McMaster 4
8 Syringe clamp-Mounted barrel clamp Custom machined 6061 aluminum 2
9 91239A152 Black finish steel button head socket cap  screw M4, McMaster 2
10 Syringe clamp-Threaded barrel clamp Custom machined 6061 auminum 2
11 57715K44 1 /4-20 x 3/4" Phenolic three arm knob with threaded stud. McMaster 4
? 60965K32 1 /4-20 x 3" Aluminum four arm knob w th threaded stud, McMaster
3 base plate Delrin base pate
14 09704IE Size 16D silicone stopper, Fisher 10
15 11553 Polycarbonate male leur lock to barb connector, fits 3/16" ID tubing, Qosina 10
16 352096 BD 15 ml syringe, modified 10
17 culture chamber top plate Machined polycarbonate 10
18 culture chamber holding plate Machined polycabonate 10
19 EW-45501 -66 Polycarbonate threaded female luer 20
20 scaffold Polyurethane Scaffold 10
21 silicone gasket Custom molded VST 50 platinum cure silicone 10
22 MS33LEAL200 Thomson Industries Inc linear motion system 1
?3 92185A969 # 10-32 Stainless Steel 44
24 11545 Polycarbonate male luer lock to barb connector, fits 1 /16" ID tubing 10
25 11556 Polycarbonate female luer lock to barb connector, fits 1/16" ID tubing 10
26 EW-064110-62 Peroxide cured silicone tubing, 1/16" ID, 1 /8" OD, 4" length 10
27 9396K203 3/16"ID 7/16" OD silicone O-ring McMaster-Carr PN 9396K203 20
28 10 ml plunger Exel Int 10ml Luer Lock Tip Plunger P/N 26265 10









NOTE: Circled dimensions 
must be 100% inspected
UNIVERISTY OF UTAH
20 S 2030 E Rm 108
Salt Lake City, 84112
TITLE:
Culture Chamber: Holding plate
SIZE DWG. NO. REV
A N/A 01
PART NO: N/A SPEC: N/A
culture chamber holding plate
SCALE: 2:1 SHEET 1 OF 1
1.000
REV DESCRIPTION DWN DATE
01 INITIAL RELEASE JK 12/2/11
.250
UNIVERISTY OF UTAH
20 S 2030 E Rm 108 
Salt Lake City, 84112
TITLE:
Culture Chamber: Top plate
SIZE DWG. NO. REV
A N/A 01
PART NO: N/A SPEC: N/A
MODEL .FILE: . . .  . . culture chamber top plate
SCALE: 2:1 fSHEET 1 OF 1
Porosity (80%± 2 % )







20 S 2030 E Rm 108
Salt Lake City, 84112
TITLE:
Scaffold
SIZE DWG. NO. REV
A N/A 01
PART NO: N/A SPEC: N/A
MODEL FILE: scaffold
SCALE: 4:1 SHEET 1 OF 1
1.250
REV DESCRIPTION DWN DATE
01 INITIAL RELEASE JK 12/2/11
1.375
UNIVERISTY OF UTAH
20 S 2030 E Rm 108
Salt Lake City, 84112
TITLE:
Silicone gasket
SIZE DWG. NO. REV
A N/A 01
PART NO: N/A SPEC: N/A
MODEL FILE: silicone gasket
SCALE: 2:1 SHEET 1 OF 1
CUT TO LENGTH 
3.410
REV DESCRIPTION DWN DATE
01 INITIAL RELEASE JK 10/25/11
UNIVERISTY OF UTAH
20 S 2030 E Rm 108
Salt Lake City, 84112
TITLE:
Reservoir
SIZE DWG. NO. REV
A N/A 01
PART NO: N/A SPEC: N/A
MODEL FILE: Reservoir












20 S 2030 E Rm 108 
Salt Lake City, 84112








Syringe clamp-Threaded plunger clamp 
SCALE: 1:2 SHEET 1 OF 1
